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ABSTRACT 
 This study examines the impact of over-the-counter (OTC) weight loss 
product television advertisements on health-related behavior. To measure potential 
exposure to television advertisements, I matched survey data on television viewing 
habits and health-related behaviors to data on television advertisements. I find 
evidence that exposure to OTC weight loss product ads increases the likelihood of 
use for such a product in women, and increases the likelihood of diet and exercise 
for both men and women. Though increased use of OTC weight loss products with 
little record of efficacy and no record for safety is troublesome, the positive spillover 
effects from the advertising complicates a possible new regulatory strategy for the 
Federal Trade Commission.  
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I. Introduction 
As the prevalence of overweight and obesity in Americans continues to rise 
(Ogden et al. 2006), people are starting to worry about the impact of excess body weight. 
Overweight and obesity affect internal organs, blood pressure (Grundy 2004), and the 
pocketbook (Durden, Huse, Ben-Joeseph et al. 2008). Since the costs (both health and 
financial) are difficult to bear, Americans are looking at different ways to lose weight. 
Some choose diet and exercise while others choose over-the counter (OTC) weight loss 
products. OTC weight loss products do not have a proven record of efficacy or safety 
(Allison et al. 2001), yet Americans still spend billions of dollars on these products each 
year (Cleland, Gross, Koss, et al. 2002). Why would consumers choose products that are 
expensive and have no proven efficacy? The answer lies in the products advertising. The 
Federal Trade Commission (FTC) has looked into the advertising (print, television, and 
internet) of OTC weight loss products and has found a large proportion of them to be 
deceptive. These ads promise get thin quick remedies (Cleland, Gross, Koss, et al. 2002) 
without lifestyle behavioral changes such as diet and exercise.  
While advertising is a profit-motivated activity of firms, it can have positive 
externalities for public health by increasing awareness of obesity, its negative health 
impacts, as well as the positive benefits of weight loss. Awareness can lead to use of the 
product and/or other behavior changes such diet and exercisewhich have positive 
health benefits. This research examines the impact of OTC weight loss product television 
ads on the consumption of an OTC weight loss product and other weight reducing health 
behaviors such as diet and exercise to determine both direct and indirect effects of the 
advertising.  
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 In this analysis, I seek to determine the effects of OTC weight loss product 
television ads on diet-related behaviors. I employ OLS regression techniques to 
determine the demographic and television characteristics manufacturers use to target their 
ads to their potential customers. Then, controlling for such targeting effects, I regress 
advertising exposure on the use of an OTC weight loss product, starting a diet, and 
exercising.  
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II. Background  
Incidence of Obesity 
Overweight and obesity are leading health crises facing America today. 
Overweight is classified as a body mass index (BMI) of 25 kg/m2 to 30 kg/m2 while 
obesity is classified as having a BMI of greater than or equal to 30 kg/m2 (Parikh, Penica, 
Wang, et al. 2007). As of 2007, sixty percent of adults in the United States were 
overweight or obese (Kaiser Family Foundation 2008).  
The incidence of obesity varies by demographic characteristics. Obesity affects 
17.1% of children and 32.2% of adults (Ogden et al. 2006). The rate of overweight and 
obesity increases until age 60, then starts to decline (U.S. Surgeon General 2001). Men 
are more likely than women to be overweight (63% vs. 47%) and non-Hispanic blacks 
have the highest incidence of overweight (66%) (CDC 2004). Mexican American men 
have a higher rate of overweight and obesity than their non-Hispanic counterparts (65% 
vs. 61%). A recent study by the Kaiser Family Foundation (2008) found that African 
Americans have the highest rate of overweight and obesity (68.9%) and Asian/Pacific 
Islanders have the lowest (37.7%). In terms of income, regardless of ethnicity, women 
who are in lower socioeconomic groups are 50% more likely to be obese than those in 
higher socioeconomic groups (U.S. Surgeon General 2001). 
The prevalence of overweight and obesity has been growing for the past 20 years 
in the United States. Overweight and obesity have doubled among adults and tripled 
among children (Ogden et al. 2006).  The Centers for Disease Control (CDC) found that 
the average U.S. adult weighs 24 more pounds than the average adult in 1960 (2004). 
One study conducted by Parikh, Pencina, Wang, et al. (2007) used data from a 5 decade 
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Framingham Heart Study to examine the trends of overweight and obesity. They found 
that among men in their nationally representative sample, overweight increased from 
21.8% to 35.2% and obesity increased from 5.8% to 14.8% between the 1950s and the 
1990s. Among women, they found that overweight increased from 15% to 33.1% and 
obesity increased from 3.9% to 14%. In conclusion, they found that overweight has 
doubled and obesity has tripled in the past 50 years. 
Obesity and Morbidity  
Obesity is the main cause of 300,000 deaths in America every year (Mokdad et al. 
2001) and is one of the leading causes of preventable death (Mokdad et al. 2004). 
Additionally, the risk of death increases as weight increases. A small weight excess of 10 
to 20 pounds can significantly increase the risk of death, especially for the middle aged. 
Compared to people with a healthy weight, obese people (BMI≥30 kg/m2) have a 50 to 
100% larger risk of early death (U.S. Surgeon General 2001). 
 Besides the increase in the risk of premature death, overweight and obesity 
increase the risk of morbidity. Obesity creates a greater risk of diabetes, hypertension, 
and hyperlipdemia. More than 80% of people with diabetes are overweight or obese and 
obese people are twice as likely to have high blood pressure. The risk of heart disease is 
increased in overweight and obese people. In addition, obesity is associated with higher 
levels of bad cholesterol and lower levels of good cholesterol (U.S. Surgeon General 
2001). Evidence suggests that the risk of these conditions can be significantly reduced 
with modest weight loss (Foster et al. 1997; Grundy 2004; Bray 2004). 
Overweight and obesity can also increase the risk of cancer. Women who have 
gained more than 20 pounds from age 18 to middle age have twice the risk of developing 
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breast cancer (U.S. Surgeon General 2001). Overweight and obesity have also been 
shown to increase the risk of colon, gall bladder, prostate, and kidney cancer (U.S. 
Surgeon General 2001). A handbook on cancer prevention estimates that obesity could 
account for 25 to 30 percent of colon, breast, endometrial, kidney, and esophageal 
cancers (Vainio and Bianchini 2002).  
Costs of Obesity 
 In addition to the health effects listed above, there are significant financial costs 
of obesity. A regression analysis using the Medical Expenditure Panel Survey (or MEPS) 
data found that in 1998 obesity-related medical expenditures reached 9.1% of all U.S. 
medical expenditures. In addition, this study found that obesity-related health 
expenditures ranged from $75 to $80 billion in 2003. Up to one half of these costs are 
financed by Medicare and Medicaid (Finkelstein et al. 2003).   
 Direct costs due to overweight and obesity include extra preventive care, 
diagnostic tests, and treatment services. Obesity is the cause of a 36% increase in 
inpatient and outpatient spending, and has also been blamed for a 77% increase in 
medication spending (Strum 2002). Indirect costs of overweight and obesity are also 
significant. Indirect costs refer to wages lost because of absenteeism (illness or disability) 
and future wages that are lost because of early death (U.S. Surgeon General 2001). 
 The costs of overweight and obesity can also be seen at the individual level. An 
overweight person will spend approximately $125 more per year and an obese person 
will spend approximately $395 more per year for inpatient and ambulatory care (Strum 
2002). Another study found that that annual direct medical costs were $147.11 higher for 
overweight people, $712.34 higher for obese people, and $1977.43 higher for severely 
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obese people (BMI>35 kg/m2) (Durden 2008).      
 One study, using MEPS data, estimated the differences in per-capita health 
spending in 1987 and 2001 by weight. The authors found that in 1987 there was a 15.2% 
difference in health spending between healthy weight and obese people. In 2001, this gap 
had risen to 37%. They also found that the rise in obese peoples health spending was 
mostly attributed to increased spending for treating diabetes, hyperlipidemia, and heart 
disease (Thorpe, Florence, Howard et al. 2004). Another study found that from age 20 to 
age 50 obese people have significantly higher health expenditures than their non-obese 
counterparts but that healthy weight people tend to have higher lifetime health 
expenditures because they live longer (Baal et al. 2007). It has also been shown that over 
the course of a lifetime, the personal costs of treating obesity are high and will deplete the 
resources from an already strained health care system (Finkelstein et al. 2008). 
Government Response to Overweight and Obesity Epidemic   
 In response to the significant health and financial effects of the overweight and 
obesity epidemic the U.S. Department of Health and Human Services (HHS) launched a 
program, Healthy People 2010. This large scale government initiative was started in 2000 
in order to set goals for better public health in 10 years (launch year was 2000). The HHS 
identified 28 focus areas in which they could improve public health. One of these focus 
areas was reducing overweight and obesity. After looking at the high morbidity and the 
direct and indirect costs associated with overweight/obesity the HHS concluded the 
prevalence of overweight and obesity should be one of the leading health indicators for 
Healthy People 2010. The stated goal of the project was reducing overweight and obesity 
to 15% of adults and 5% of children by 2010.  Specifically, the HHS had specific goals in 
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reducing overweight and obesity among African Americans and Hispanics (who have 
higher rates of overweight and obesity). In order to do this, the HHS devised a series of 
public awareness campaigns about the effects of overweight, obesity, diet, and exercise. 
They also launched different programs trying to improve nutrition and make exercise 
opportunities more accessible to the public (United States Department of Health and 
Human Services 2000).        
 A mid-decade review of the program found that there has been no movement 
towards the overall goal of reducing overweight and obesity. In fact, the mid-course 
review found that the U.S. population had moved further away from the goals stated in 
the original Healthy People 2010. Overweight and obesity had increased among African 
Americans and Hispanics, which are the demographic groups that the HHS had 
specifically targeted (United States Department of Health and Human Services 2005). 
Medical Opinions on Healthy Weight Loss Levels    
 Medical experts have come to a broad consensus on healthy ways to lose weight. 
The FTC recommends that overweight and obese people should reduce their caloric 
intake by 500 to 1,000 calories a day in order to achieve a healthy weight loss of 1 lb per 
week (Cleland, Gross, Koss et al. 2002). A study by Weinsier, Wilson, and Lee (1995) 
looked at the risk of gallstone formation during weight loss. They found that in order to 
keep this risk low, heavy individuals should not exceed a weight loss of 3.3 lbs/week. 
Another study puts the maximum healthy weight loss at 1 lb/week (Drewnewski and 
Petersmarck 1990). Different government agencies have agreed with these guidelines, 
saying that safe weight loss falls between .5-2 lbs/week (U.S. Congress, Department of 
Agriculture, Department of Health and Human Services 2002). 
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Efficacy of Diet and Exercise 
 Medical research has repeatedly shown that the most effective method of losing 
weight is a combination of reduced caloric intake (diet) and exercise. A meta-analysis of 
available research by Miller, Koceja, and Hamilton (1997) compared subjects across 
studies to determine the most effective methods of weight loss. Using an ANOVA 
analysis they looked at the mean levels of weight loss for all participants and how the 
mean weight loss differs by method. They found mean weight loss (after one year) for 
diet, exercise, and diet and exercise programs at 10.7kg, 2.9kg, and 11 kg, respectively. 
Miller et al. concluded that the current weight loss research shows that while diet and 
exercise are each effective separately, they have their greatest effect when used in 
combination. An experiment with sedentary women found weight loss significantly 
correlated with the level of physical activity. The authors of this study recommend 
exercise of 150 minutes a week for sedentary adults in conjunction with a diet (Jakicic et 
al. 2003). Based on a comprehensive review of diet and exercise research, the National 
Heart, Lung, and Blood Institute (NHLBI) recommends a reduced calorie diet and an 
increased physical activity program to reduce weight in overweight and obese individuals 
(NHLBI 2001). 
 Research has also shown that diet and exercise are the best methods available for 
keeping weight off in the long term. The National Weight Control Registry provides data 
about different weight loss strategies and how often they succeed. Members of this 
registry who were able to keep the weight off engaged in long term strategies. They kept 
exercising (mean=1 hr/day), ate a reduced calorie and low fat diet, and kept their diet and 
exercise habits consistent from weekday to weekend (Wing and Phelan 2005). 
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Prevalence of Diet and Exercise 
 
Individuals have heard the advice from the medical community and many choose 
diet and exercise as their preferred method for weight loss. Over 25% of people report 
trying to control their diet in the past 12 months (NCS 2008). Another study using the 
National Health Interview Survey found that 24% of men and 38% of women were trying 
to lose weight. The study found that the most prevalent methods of weight loss among 
these respondents were eating reduced calorie diets (58% men, 63% women); eating low 
fat diets (49% men, 56% women); and increased physical activity (54% men, 52% 
women) (Kruger, Galuska, Serdula, et al. 2004). Using a random digit dialer, a study by 
Levy and Heaton found similar results to Kruger et al. with 62% of men and 71% of 
women trying to lose weight using diet and exercise as part of their overall weight loss 
strategy (Levy and Heaton 1993). An additional phone survey found that 54% of 
respondents had lost 10% of their maximum weight in their lifetime with half of these 
cases being the result of diet and exercise (McGuire, Wing, and Hill 1999). A study by 
Serdula, Collins, Williamson et al. (1999) found a lower prevalence of diet and exercise. 
Their study found that only 21.5% of men and 19.4% of women who were attempting to 
lose weight used the method of a reduced calorie diet and 150 minutes of exercise/week. 
Approximately 80% of people in this study were using methods such as diet, exercise, 
ineffective amounts of exercise, and products to aid in weight loss. 
In addition to looking at rates of diet and exercise, some studies found a sizeable 
percentage of respondents using over the counter (OTC) weight loss pills in order to aid 
in weight loss. Kruger et al. found that only 2% of men and 3% of women chose diet pills 
as their preferred method of weight loss (Kruger 2004). In contrast, Levy and Heaton 
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(1993) found a higher level of diet pill use, 7% of men and 14% of women.  In summary, 
diet and exercise remain the main strategies among Americans trying to lose weight 
(Kruger et al. 2004; Levy and Heaton 1993; McGuire et al. 1999; Serdula 1999) and the 
market for OTC products is estimated at between 2% and 15% of the consumers who are 
trying to lose weight.  
Market for Weight Loss Products 
 Marketdata Inc. published a detailed review of the weight loss market in 2007. 
They projected a 6% annual growth rate for the entire market and estimated that the 
entire weight loss market would reach $68.7 billion in 2010. Their analysis was 
concerned with the entire weight loss market (including exercise programs, diet shakes, 
Jenny Craig/Weight Watchers, etc.), not just OTC weight loss products (Marketdata Inc. 
2007). In their report, Cleland, Gross, Koss et al. (2002) found the weight-loss 
supplement market (OTC products) to total about $4.6 billion in 1999. 
 Several studies have been done to determine who is using OTC weight loss 
products. Pillitteri, Shiffman, Rohay, et al. (2008) found that of people who had made 
weight loss attempts, 33.9% reported using an OTC weight loss product at some time. 
This use was much higher among women than men and much higher among young 
people. In addition, the authors found that many consumers had misconceptions about the 
products in that they thought that they were evaluated for efficacy and safety by the FDA. 
A similar phone study by Weiss et al. (2006) found that 12% of respondents trying to lose 
weight have used a nonprescription product to aid in weight loss. 
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Efficacy of Weight Loss Products 
Although OTC weight loss products have flooded the market, these products have 
little proven efficacy and many have yet to be scientifically evaluated (Williamson and 
Bowman 2001). In contrast to the scientifically proven diet and exercise method, OTC 
weight loss products do not promote significant long-term weight loss. In addition, many 
have been pulled from the market because of safety concerns. 
Phenylpropanolamine (PPA) was the chemical compound favored by OTC 
product manufacturers prior to 2000. This product was believed to increase metabolism 
by increasing blood pressure and heart rate. Products such as Dexatrim and Acutrim used 
this compound in their products. Peer reviewed randomized controlled studies have 
pointed to the dubious efficacy of PPA in promoting long-term weight loss. Greenway 
(1992) performed a detailed meta-analysis on all of the parallel double-blind studies 
testing the effects of PPA and concluded that PPA did provide small, significant amounts 
of weight loss when compared to a placebo. Greenway cautioned about the small sample 
size in most of these studies and the fact that large scaled studies on PPA had yet to be 
attempted. The studies all pointed to only short-term weight loss and no published studies 
credited PPA with successful long-term weight loss.  Alger, Larson, Boyce et al. (1993) 
tested the effects of PPA on energy expenditure and weight loss in overweight women. 
Although they found slightly more weight loss in the group taking PPA (-5 kg over 7 
weeks) when compared to the placebo group (-3 kg over 7 weeks) they found no 
significant difference in energy expenditures. The authors recognize that this study 
cannot provide conclusive evidence in favor of PPA because of the small sample (n=18).  
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Due to research linking an increased risk of hemorrhagic stroke in patients taking 
products containing PPA, in November 2000 the FDA asked drug manufacturers to 
voluntarily withdraw PPA containing products from the market until large scale research 
could be performed on its safety. In 2005, the FDA proposed a rule to ban PPA and put 
out a public health advisory. The risk of hemorrhagic stroke was significant and the FDA 
recommended that consumers not use any products that have PPA (FDA 2005). 
Since PPA was no longer an option, many manufacturers turned to ephedra to 
stimulate weight loss. This product stimulated weight loss in a similar fashion to PPA by 
speeding up the metabolism, and could also be used as an appetite suppressant. Many 
products, such as Xenadrine and Ultimate Orange used ephedra as a main ingredient.  
Boozer, Daly, and Homel (2002) conducted a 6-month randomized, double-blind 
placebo controlled trial of ephedra. They found that ephedra did produce modest weight 
loss and reduction in body fat when compared to a placebo. Shekelle, Hardy, and Morton 
(2003) provided a more detailed meta-analysis of all research studies evaluating the 
efficacy and safety of ephedra. They found that ephedra did promote modest weight loss 
of about .9 kg/month more than a placebo. None of the studies in the meta-analysis lasted 
for more than 6 months so there was no evidence for the long-term efficacy of ephedra. 
The studies reviewed in the meta-analysis also pointed to an increased risk of psychiatric, 
autonomic, gastrointestinal symptoms, and an increased risk of heart palpitations in 
ephedra patients.  
After a review of medial evidence the FDA found an increased risk of stroke and 
death in consumers using ephedra. In addition, they reported that the harmful effects of 
ephedra worsened when combined with caffeine (another common ingredient in OTC 
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weight loss products). In response to the danger posed by ephedra, the FDA banned 
ephedra in 2004. After a lengthy appeals process, the Court of Appeals ruled in favor of 
the FDA and left the ban in place (FDA 2006).  
After the ban of ephedra, several manufacturers turned to citrus aurantium, a 
product very chemically similar to ephedra. Many commonly recognized products, such 
as Trimspa, Metabolife, and Xenadrine, use this ingredient. It is also the active ingredient 
in many supplements that have ephedra free on the label.  
Bent et al. (2003) performed a meta-analysis of available research concerning the 
efficacy of citrus aurantium. This study showed no statistically significant benefit for 
weight loss and provided no information regarding the safety of this bitter orange. 
Another study by Dwyer et al. (2005) concluded citrus aurantium has not been shown to 
promote weight loss in any available research.  
The most extensive analysis of the safety and efficacy of OTC weight loss 
products was conducted by Allison, Fontaine, Heshka et al. (2001). They identified 18 
alternative methods or products that have been claimed to reduce fat and promote 
weight loss. They looked at peer-reviewed research examining the weight loss efficacy of 
methods such as acupuncture, aromatherapy, hypnosis, subliminal suggestions; 
ingredients such as bladderwrack, chitosan, chromium, conjugated linoleic acid, 
dehydroepiandrosterone, garcinia cambogia, germander, ma huang (ephedra), ß-hydroxy- 
ß methylbutyrate, platago, pyruvate, St. Johns wort, sunflower; and thigh creams. After 
this extensive review, the authors concluded that there was no significant evidence that 
any of these common weight loss methods, ingredients, or products induced significant 
long-term weight loss. None of these products had more than two randomized double-
 18
blind placebo controlled studies and all weight loss as a result of the product was modest 
at best. In addition, the authors said that none of the studies have shown proven long-term 
safety associated with a method, ingredient, or product (Allison et al. 2001).  
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III. Regulatory Background 
Safety Regulation 
In 1994, Congress passed the Dietary Supplement Health and Education Act 
(DSHEA). This law placed dietary supplements into a different class of regulation from 
prescription drugs. This category includes vitamins, minerals, herbs, amino acids, a 
concentrate, or a metabolite. No pre-market approval by the FDA is needed for the sale of 
dietary supplements and they are not evaluated by the FDA for efficacy or safety prior to 
sale. In effect, the DSHEA treats the regulation of OTC weight loss supplements in the 
same way it would treat a food (Cleland, Gross, Koss, & Muoio 2002). The text of the 
DSHEA that discuses this classification of dietary supplements can be found in Appendix 
1 (21 U.S.C. 321).          
 The FDA can still ban a dietary supplement once it is determined to be unsafe. 
This reactionary power can only be exercised once the product is already on the market 
and determined to be unsafe. As mentioned earlier, the FDA did ban the use of PPA and 
ephedra because of safety concerns (FDA 2005; FDA 2006). However, this reactionary 
power of the FDA can negatively affect consumer health by exposing them to harmful 
and undisclosed side effects (Baron 2004).            
Advertising Regulation       
 Although the FDA has the power to pull an unsafe product from the market, the 
FTC is in charge of regulating OTC weight loss advertising. The FTC Act (15 U.S.C. 
§41-58) makes false advertising illegal and the FTC has a right to bring suit against a 
company for false advertisements (§52 and 54). Although the threat of a suit by the FTC 
was thought to be enough of a deterrent, Rotfeld (2003) notes that false advertising is still 
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rampant in the market, and that there are far too many companies producing these false 
claims in advertising for the FTC strategy of bringing lawsuits to be effective. He argues 
for a policy of strict liability against the disseminators (media vehicles such as magazine 
publishers and television network owners). Galloway echoes Rotfelds concerns and calls 
for suits against media vehicles stating that the FTC has depended on self-regulation by 
the industry which has proved dismal (Galloway 2003).     
 The DSHEA requires that advertisements for OTC weight loss products (dietary 
supplements) not claim that they can treat or cure a disease (such as obesity) (21 U.S.C. 
321). Lewis argues that the companies have maneuvered around the DSHEA and have 
made health-outcome claims in their ads. The manufacturers are able to do this by 
placing disclaimers in their ads that say this product has not been shown to treat or cure 
any disease or product has not been evaluated by the Food and Drug Administration. 
These disclaimers tend to be the bottom of the screen in television ads and voiced over in 
very fast speech (Lewis 2001).        
 The FTC responded with a set of industry guidelines for weight loss product 
advertising (2003). An FTC report identified seven red flag claims that should not 
appear in OTC weight loss ads: 
1- Product causes weight loss of two pounds or more a week for a month or more 
without dieting or exercising 
2- Product causes substantial weight loss no matter what or how much the 
consumer eats 
3- Product causes permanent weight loss (even when the consumer stops using 
the product) 
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4- Product blocks the absorption of fat or calories to enable consumers to lose 
substantial weight 
5- Product safely enables consumers to lose more than three pounds per week for 
more than four weeks 
6- Product causes substantial weight loss for all users 
7- Product causes substantial weight loss by wearing it on the body or rubbing it 
into the skin  
In addition to the above mentioned claims the FTC provided detailed rules and 
examples for what constituted a red flag violation. Preliminary research has shown that 
the initiative has significantly reduced the prevalence of red flag violations in print 
advertising since the rules were presented to the magazine publishers (Avery, Cawley, 
Eisenberg 2008).  
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IV. OTC Weight Loss Product Advertising 
Content of OTC Weight Loss Product Ads 
The FTC convened a conference in 2002 to address this problem in OTC weight 
loss advertising. In conjunction with the conference, Cleland, Gross, Koss et al. released 
a comprehensive review of deception in OTC weight loss ads. They collected a sample of 
300 advertisements across print media, television, and the Internet. After a detailed 
content analysis, they found that many of the ads included exaggerated, unsubstantiated, 
or false claims. They understood some claims to be false because the scientific 
community had ruled that there was no possible way for a supplement to do what the ads 
claimed. For example, current scientific knowledge suggests that dietary supplements are 
unable to block the absorption of fat into the systemyet many ads claim that their 
products do just that. 
Cleland, Gross, Koss et al. (2002) found the following to be the most common 
marketing techniques used in the 300 weight-loss advertisements they studied: 
• Consumer testimonials/Before and after photos rarely portrayed realistic weight 
loss goals, and images were often distorted. They found that the average weight 
losses claimed (more than 76 percent of the sample claimed weight loss above 70 
pounds) were simply not achievable for the products advertised.  
• Rapid weight loss claims that were obviously false, e.g., greater than 8-10 pounds 
per week. 
• Claiming no diet or exercise needed with the product to lose weight, i.e., that 
results can be achieved without reducing caloric intake or increasing physical 
activity, with some ads even claiming that you can eat as much as you want and 
still lose weight. 
• Claims of long term weight loss that are clearly untrue, e.g., take it off and keep 
it off. 
• Claims to be clinically proven or doctor-approved, with most ads failing to 
provide consumers with sufficient information to allow them to verify the 
advertisers representations. 
• Claims of safe and natural weight loss, with many of the ads failing to include 
active ingredients in the product and evidence of safety. 
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Cleland et al. also compared differences in marketing techniques from 1992 to 
2001. The found that the number of unique ads for OTC weight loss products had 
increased three fold, the frequency of OTC weight loss product ad appearances had 
doubled, and the proportion of supplement ads to other, more efficacious products (such 
as Weight Watchers, Jenny Craig, or Nutrisystem), had significantly increased. In 
addition, in 2001 ads were significantly more likely to include dramatic testimonials, 
before/after photos, promise permanent weight loss, guarantee weight loss success, claim 
that weight loss can be achieved without diet and exercise, claim that results can be 
achieved quickly, claim that the product is all natural, and make explicit or implied 
claims that the product is safe. 
 Appalled by the sheer number of ads with deceptive claims (40% for certain, 
probably closer to 55%), Cleland, Gross, Koss et al. made recommendations to the FTC 
for a concrete set of advertising standards for the industry. They based their 
recommendations on a set of claims that appeared in ads and were known to be false. 
They recommended that the FTC employ a more heavy hand when it comes to 
enforcement against deceptive advertising.  
Effects of Advertising on the Consumer- Individual Level 
Very little research has been done on the effect of over-the-counter product 
advertisements on the consumerand even less on the effect of television OTC ads. A 
study by Avery, Kenkel, Lillard, and Mathios (2007) examined the effect of OTC 
smoking cessation print ads on smoking cessation behavior using a rigorous model that 
accounted for potential targeting effects by the advertisers. They analyzed the impact of 
ad exposure at the individual level and were able to conclude that exposure to OTC 
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smoking cessation print ads significantly increased the likelihood of a consumer quitting 
smoking. A study by Avery, Simon, and Eisenberg (2008) used the same individual-level 
data to examine the impact of Rx antidepressant print ads on the use of an antidepressant. 
Controlling for various demographic characteristics as well as reading intensity, they 
found that exposure to antidepressant magazine ads has a significant impact on the 
likelihood of antidepressant use. This same study also examined Rx antidepressant 
television ads, but found no significant effects.  
In summary, research that has examined the individual level impact of OTC and 
Rx print ads has found significant effects on product use, but no evidence for the effect of 
television advertising suggesting the effects may be different. A study by Barlow and 
Wogalter (1992) evaluated the differences in print and television medias ability to 
convey message warnings. The authors looked at warnings in alcohol advertisements. By 
using a randomized experiment, they found that participants exposed to print ads were 
able to retain more detailed information when compared to the group exposed to 
television advertisements. The authors suggested that reading a print advertisement is a 
much more active process than watching a television advertisement. They concluded that 
consumers tend to be doing other things when watching television and thus pay less 
attention to the advertisements. Another potential factor limiting the efficacy of television 
advertising is the increasing prevalence of zapping through the commercials. When an 
advertisement comes on, the consumer can channel surf, grab a snack, read the 
newspaper, or fast forward through the commercial if they have Tivo or a Digital Video 
Recording (DVR). Using a survey of zappers and nonzappers Tse and Lee (2001) 
found that nonzappers had significantly higher brand recall ads at the end of the program 
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(in between programs) were more effective because the end of a show has the least 
zapping potential since consumers are getting ready to watch the next program. In 
summary, although research has shown significant effects of Rx and OTC product 
advertising in print media (Avery et al. 2007; Avery et al. 2008) it is hard to extrapolate 
this information to television advertisements because of the differences in media impact 
and characteristic (Barlow and Wogalter 1992; Tse & Lee 2001).  
Effects of Advertising- Market Level 
Direct to consumer advertising has been thought to increase drugs sales. This is in 
line with Bagwells economic theory of advertising (2005), because the ads would not be 
on the air if they did not increase drug manufacturers profits. A study by Rosenthal et al. 
(2003) looked at how changes in DTC advertising and detailing affected drug sales. The 
study found a .10 demand elasticity, or on average a 10% increase in DTC advertising 
resulted in a 1% increase of sales. However, increased sales did not directly correspond to 
the product, but to the class of drugs. In other words, a 10% increase in all cholesterol 
DTC advertising resulted in a 1% increase in all prescription cholesterol product sales. 
This study did not find that increased DTC advertising increased a particular brands 
relative market share. 
Other studies have examined the return on investments (ROIs) for DTC 
advertising. Gascoigne and Busbice studied 64 different drugs and found for every $1 of 
DTC advertising the companies would get $2.20 in increased sales (Gascoigne and 
Busbice 2006). Another study examined the effects of DTC advertising in specific brands 
(49 drugs). They found that 90% of the drugs had a positive ROI for their DTC 
advertising. In addition, they found that 70% of the drugs had a ROI of more than $1.50 
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for each $1 of advertising and 35% of drugs had an ROI of more than $2.50 for each $1 
of advertising (IMS Management Consulting 2004). 
 A study by Donahue et al. (2004) examined the effect of DTC antidepressant 
advertising on increased prescriptions. They used market-level data to look at the level of 
prescriptions when DTC antidepressant advertising was high and the level of 
prescriptions when DTC antidepressant advertising was low. They found that individuals 
who are diagnosed when DTC antidepressant advertising was high had a 32% higher 
relative odds of starting treatment with the drug as opposed to those who were diagnosed 
when DTC antidepressant advertising was low (Donohue et al. 2004). 
 In summary, market-level analysis has shown that the DTC advertising has a 
significant effect on market sales. OTC weight loss advertising is likely to have a larger 
effect because the advertising level is higher and there is no need to obtain a prescription 
from a physician. Still, this market-level analysis was unable to examine the effects of 
television advertising on individual consumers, relying instead on the assumption that all 
people who live in the same area view the same advertisements.  
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V. Research Objectives 
Research indicates that obesity is widespread and increasing in America (U.S. 
Surgeon General 2001; Ogden et al. 2006) and harmful to public health (Finkelstein et al. 
2003; Strum et al. 2002; Mokdad et al. 2001; Mokdad et al. 2004). The market has 
responded to this epidemic by producing hundreds of OTC weight loss products that have 
little to no proven efficacy (Allison et al. 2001). A large proportion of the advertising for 
these products remains deceptive (Cleland, Gross, Koss, et al. 2002), despite FTC 
attempts to guide self-regulation by the industry (FTC 2003). The question remaining is 
whether this advertising is harmful to consumers and the degree to which television 
advertisements for these products encourages product use.   
Although significant impacts of advertising on product use have been found for 
ads in print media (Avery, Cawley, Eisenberg 2008), these findings can not be directly 
extrapolated to television advertisements (Barlow and Wogalter 1992; Tse & Lee 2001). 
Therefore, this study will fill a gap in the existing literature and assess the effect of OTC 
weight loss product advertisements in the media of television on the individuals decision 
to consume OTC weight loss products. 
In order to examine the impact of level exposure to OTC television weight loss 
ads on consumption of weight loss products and postulate spillover effects it is necessary 
to control for characteristics of consumers that would be used by marketers in their 
advertising targeting efforts. The individual-level data used in this study are the same 
data used by marketers for their media planning decisions. The first step in this analysis, 
therefore, is to determine the measurable census characteristics that could be expected to 
result in greater exposure to OTC weight loss product advertising. The same 
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characteristics are then controlled for in examining the impact of level of advertising 
exposure on product purchase and spillover effects.  
Controlling for the characteristics of individuals used by marketers in their 
targeting behavior the following two questions are addressed: 
1. Do these ads make the consumer more likely to purchase an OTC 
weight loss product? 
2. Do these ads have positive spillover effects such as increased 
probability of starting a diet, exercising, or both? 
For question one, I hypothesize that these ads will significantly increase the 
likelihood of product purchase by the consumer. As stated by Bagwell (2005), firms are 
profit maximizing rational actors that will increase their advertising budget only if sales 
will likely increase.  
For question two, I hypothesize that these ads will have a significant spillover 
effects on other obesity related behaviors such as diet and exercise. If a consumer is 
inundated with these advertisements, they will be thinking about weight loss more. Many 
consumers know that the right method of weight loss is diet and exercise, even if they 
continue their search for a quick fix product. However, I expect an indirect effect to be 
smaller than the direct effect of product use.  
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VI. Methods  
Description of Data 
Television  Data- TNS Media Intelligence 
Data provided by TNS included OTC weight loss ads that appeared on television 
from 1999-2004. Only data from 2001-2004 were used to match the individual-level 
described in the following section. The data provided ad information from network 
television, cable, and local spot markets. From 1999-2001 the TNS data cover local spot 
ads for the largest 75 designated marketing areas (DMAs); from 2002 - 2004 the TNS 
data cover the largest 100 DMAs. The TNS data represent all national network and 
national cable ads, and includes all local ads that aired on network television. The dataset 
does not include local cable ads. 
The TNS data provide information on the exact time and date of airing each 
product ad. I sorted the ads by product name and kept only ads for OTC weight loss pills. 
I did not include diet shakes, exercise programs, or diet programs (Weight Watchers, 
Jenny Craig, etc).  The data was limited to ads for pills because the individual-level data 
asked respondents if they had purchased an OTC weight loss pill.   
Individual Level Data- Simmons National Consumer Survey 
The National Consumer Survey (NCS) is a nationally representative repeated 
cross-sectional survey, where the sample for each wave is an independently drawn multi-
stage stratified probability sample. The NCS is a marketing survey that asks consumers 
about their television viewing habits as well as various health related outcomes (using an 
OTC weight loss product, starting a diet, exercising, or both). I used data from eight 
survey waves that were administered between 2001 and 2004.  
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 The NCS provide data on the specific television viewing habits of respondents. 
Specifically, the NCS asked respondents how often they watch certain shows, separating 
by network and syndication status.1 The NCS data also provide detailed demographic 
data regarding age, race, gender, education, household income, Census region, marital 
status, and employment characteristics. These variables provided important exposure 
controls in the analysis.  
 
Measures 
Outcomes 
 The three main outcome measures used in the analysis are whether the 
respondents have used an over-the-counter weight loss pill in the past 12 months, have 
been controlling their diet in the past 12 months, and whether the respondent exercises at 
least once a week The last two measures are used to create a variable that equals one if 
the respondent reported both controlling their diet in the past 12 months and exercising at 
least once a week.  
Advertising Exposure Effects 
To estimate consumers potential exposure of OTC weight loss television ads, I 
matched TNS ads from shows that respondents reported viewing regularly to ads that 
have appeared on those programs. The NCS asks respondents about over 400 television 
shows and how often they watch them. In order to match the ads, I took the number of 
ads that appeared on that show one year prior to their survey date and multiplied it by 
how often they reported watching that show. Then I summed across all the television 
                                                
1 For example, the NCS asks viewing behavior for Simpsons repeats (shown daily) and viewing behavior 
for new Simpsons episodes (aired weekly).  
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shows the respondent reported watching in the past 12 months to get their potential 
exposure to OTC weight loss television ads for the past 12 months. This 12 month period 
is consistent with Bagwells economic theory of advertising. Based on his analysis, he 
concludes the staying power of an advertisement to be about 9 months (2005). Survey 
waves in the NCS allow for 6 or 12 month exposure windows, so the 12 month window 
was chosen for this study. This 12 month ad exposure window is consistent with similar 
measures used in the analysis of individual-level data (Avery et al. 2007; Avery et. al 
2008). In addition, this 12 month window corresponds with the respondents answers to 
questions regarding their diet pill use, diet and exercise behavior obtained form the NCS 
data.  
Although this method of matching ads was fairly straightforward for national ads, 
in order to match local or spot ads, the DMA of the NCS respondent has to be known. 
Since the DMA can only be identified for certain respondents in the NCS data (see DMA 
matching process used in Avery, Lillard, Mathios & Kenkel 2008), the sample is limited 
to respondents for whom a DMA of residence can be identified (N=59,831). Limiting the 
sample in this way doesnt have an appreciable impact on the analysis because the sub 
sample is very similar to the full sample of NCS respondents (Appendix 2). 
To summarize, the ad exposure measures how often a respondent watches a 
television show, multiplied by the number of ads that have appeared on that show in the 
12 months prior to the survey date, summed across all television shows that the 
respondent reports watching. The exposure variable ranges from 0 to 5,535 ads with a 
mean of 178 ads and a standard deviation of 225 ads. The variable is heavily left skewed 
with ten percent of respondents seeing zero advertisements (see Figure One). The mass of 
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the distribution occurs close to zero, with a few respondents exposed to very large 
numbers of ads. Due to the highly skewed nature of the variable entering it into the model 
as a continuous variable would not capture the exposure level effects very well. For this 
reason the exposure measure was separated into three dummy variables. No ad exposure, 
low ad exposure between 1 and 178 ads (the mean number of ads), and high ad exposure 
greater than 178 ads2.  
                                                
2 Alternative specifications were used with exposure estimated as a continuous measure (number of ads) 
and natural log of the number of ads. Although these measures produced sign coefficients, they were close 
to 0. In addition, an alternative specification was used with the median number of ads (109) as the exposure 
cut off but it was not significantly different in sign or magnitude from the model using the mean number of 
ads. 
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Exposure is not a perfect measure to analyze the effects of advertising on the 
consumer. We do not know if the consumer actually watched the ads that they were 
exposed to or if they paid any attention to them. However, the exposure measure 
represents a vast improvement over market level analysis that assumes all consumers who 
live in the same area see the same advertisements, regardless of which television shows 
they watch. 
Demographic and Media Behavior Variables 
The set of demographic variables used in the analysis are gender, age, 
race/ethnicity, education, income, marital status, family size, employment status, and 
census region. Table 5 provides information on how each of these variables were coded 
for the analysis. In addition to demographic variables, measures were created to capture 
the television viewing habits of individuals. People watch different amounts of television 
and different types of shows and will therefore be exposed to different amounts of 
advertising. The first measure was the average number of hours spent viewing television 
in the average week. The mean number of hours spent watching television captures the 
variance in ad exposure based on the hours of television watched. Next, a set of dummy 
variables was created for type of television show represented in the data. The television 
categories placed each of the television shows into a category based on their content-- 
this set of television program dummies is described in table 4. Since marketers know the 
characteristics of individuals who watch different types of television shows, these 
program variables will capture variance in exposure to OTC weight loss product ads 
accounted for by the types of program an individual watches. 
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Since the NCS is a repeated cross sectional survey drawn during different time 
periods between 2001-2004, a set of wave dummies was created to indicate the time 
period the respondent was surveyed. 
 
Regression Analysis 
 The first model was estimated to examine how level of ad exposure varies by 
demographic characteristics of respondents. The model is: 
Number of Ads = α + δDi + σTCi + φHi + µWi + εi                                        (1) 
Where: 
D    =  vector of demographic control variables 
TC =  vector of program control variables 
H   =  control for television viewing intensity 
W   =  NCS wave dummies 
ε     =  idiosyncratic error term. 
             
The models for diet-related behavior are:  
Prob(Pi) = α + βTVi + δDi + σTCi + φHi + µWi + εi                                        (2) 
Prob(DIi) = α + βTVi + δDi + σTCi + φHi + µWi + εi               (3) 
Prob(Ei) = α + βTVi + δDi + σTCi + φHi + µWi + εi              (4) 
Prob(DEi) = α + βTVi + δDi + σTCi + φHi + µWi + εi                         (5)                                                    
Where: 
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P    =  a dummy variable for whether the individual (i) uses an OTC weight loss   
 pill 
DI   =  a dummy variable for whether the individual (i) is dieting 
E    =  a dummy variable for whether the individual (i) exercises 
DE  =  a dummy variable for whether the individual (i) is dieting and exercises 
TV  =  television advertising exposure of individuals 
D    =  vector of demographic control variables 
TC =  controls for types of programs watched 
H   =  control for television viewing intensity 
W   =  NCS wave dummies 
ε     =  idiosyncratic error term. 
 Models (2) through (5) were estimated as logits. A logit model is appropriate 
for binary dependent variables since it was a logistic cumulative probability distribution  
that produces probabilities between 0 and 1. While a probit would assume the outcome 
measure to be normally distributed between 0 and 1, logits will account for the skewed 
nature of the outcome measures. This is the most appropriate estimation method to use, as 
all of the dependent variables are binary (Stock and Watson 2007). Since the literature 
suggests such gender disparities in overweight, obesity, prevalence of diet, exercise, and 
OTC weight loss products, men and women experience the epidemic of overweight and 
obesity in completely different ways. In order to look at gender in separate ways, each 
model was run twice, once for men and once for women.3 
 
                                                
3 A combined model of men and women was also estimated. Although this model produced significant 
effects, the divergent effects from separate models provided a more thorough examination of the research 
questions. 
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VII. Results 
Characteristics of OTC Weight Loss Ad Airings 
Table 1: Number of Ads by Year, 2000-2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Number of Ads by Day of Airing, 2000-2004 
 
Day of Week Freq. Percent 
Sunday 84,333 9.66
Monday 143,730 16.47
Tuesday 139,235 15.95
Wednesday 130,062 14.90
Thursday 145,164 16.63
Friday 143,165 16.40
Saturday 87,159 9.99
TOTAL 872,848 100.00
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Year Freq. Percent 
Percent 
Change
2000 132,794 15.21  
2001 176,131 20.18 32.63
2002 201,003 23.03 14.12
2003 182,044 20.86 -9.43
2004 180,876 20.72 -0.64
TOTAL 872,848 100.00  
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Table 3: Number of Ads by Month of Airing, 2000-2004 
 
Month Freq. Percent
January 120,962 13.86
February 64,781 7.42
March 84,995 9.74
April 126,269 14.47
May 103,875 11.90
June 97,481 11.17
July 59,487 6.82
August 89,290 10.23
September 43,703 5.01
October 42,425 4.86
November 12,596 1.44
December 26,984 3.09
TOTAL 872,848 100
 
A total of 872,848 OTC weight loss product ads appeared during the sample 
period (table 1). The number of ads increase steadily from 2000 to 2002 and then 
decrease back to 2001 levels for 2003 and 2004. As seen in table 2, the timing of these 
ads differs by both day of airing and month of airing. The majority of these ads appeared 
Monday to Friday (80.35%). This concentration of weekday ads is most likely to the drop 
off in television audience during the weekends. A larger number of ads are aired in 
January (~13.86%) when people are likely to resolve to lose weight as part of their New 
Years resolutions. In addition, the number of ads is high during the months leading up to 
the summer when people are trying to lose weight for the summer season (April~14.5%; 
May ~12%; June~11%). The number of ads is lower during the holiday months when less 
people are thinking about losing weight (November ~1%; December~3%). 
Table 4 examines ads by television program categories. Morning news programs 
contain the largest number of OTC weight loss ads (~22%) followed by day-time talk 
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shows (~16%). Daytime talk shows tend to be more heavily viewed by women. OTC 
weight loss product ads are seldom seen during cartoons (.08%) and history/biography 
shows (.06%). 
Table 4: Number of Ads by Television Category, 2000-2004 
Category Freq. Percent Ads/Hour 
Morning news program 188,514 21.6 5.38 
Day time talk show 136,178 15.6 3.89 
Other Category2 89,495 10.25 2.55 
Sitcoms 77,965 8.93 2.23 
Daytime soap operas 67,131 7.69 1.92 
Court TV programs1 44,381 5.08 1.27 
Dramas 42,009 4.81 1.20 
Reality Shows 41,542 4.76 1.19 
Quiz/competitive show (day or 
evening) 41,255 4.73 1.18 
Movie reruns/made for TV movies 33,231 3.81 0.95 
Celebrity News Programs 29,027 3.33 0.83 
Late night talk show 20,870 2.39 0.60 
Sports 16,028 1.84 0.46 
Cooking/Home shows 10,039 1.15 0.29 
Variety/Music programs 9,951 1.14 0.28 
Science Fiction Programs 7,455 0.85 0.21 
Magazine programs3 7,228 0.83 0.21 
Evening/late night new programs 4,515 0.52 0.13 
Political Analysis/Discussion 
Program 2,715 0.31 0.08 
Health and Fitness Programs 727 0.08 0.02 
Nature/Wildlife 704 0.08 0.02 
Cartoons 673 0.08 0.02 
History/Biography 560 0.06 0.02 
Awards Shows4 371 0.04 0.01 
Medical programs 284 0.03 0.01 
TOTAL 872,848 100 1.00 
1Example: Judge Judy 
2The other category is made up of difficult to categorize program. Despite best efforts 
to determine the category of these programs, they were not able to be categorized. 
Programs in this category had abbreviated names such as SHOW or REAL and could 
not be classified.  
3Example: 20/20, Dateline, etc. 
4Example: Oscars, music awards, etc. 
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Table 5: Distribution of NCS Respondents by Demographic Characteristic 
 Freq. Percent 
Gender:   
Male 26,806 44.80 
Female 33,025 55.20 
Age:   
18-24 6,027 10.07 
25-34 9,118 15.24 
35-44 12,415 20.75 
45-54 12,535 20.95 
55+ 19,736 32.99 
Race:   
White 43,202 72.21 
Black 3,941 6.59 
Hispanic 9,792 16.37 
Other 2,896 4.84 
Education:   
Less than HS 7,343 12.27 
HS Grad 16,063 26.85 
Some College 16,601 27.75 
College Grad 19,552 32.68 
Income:   
< $32,500 8,076 13.50 
$32,501 - $55,000 10,636 17.78 
$55,001 - $87,500 13,599 22.73 
$87,501 - $125,000 19,426 32.47 
> $125,001 8,094 13.53 
Married Status:   
Single 11,409 19.07 
Married 38,858 64.95 
Divorce/Seperated/Widowed 9,040 15.11 
Size of Family:   
1 5,476 9.15 
2 19,820 33.13 
3 11,719 19.59 
4 11,359 18.99 
5+ 5,905 9.87 
Employment Status:   
Not Employed 20,874 34.89 
Employed 38,957 65.11 
Census Region:   
Northeast 14,984 25.04 
South 16,781 28.05 
Midwest 15,112 25.26 
West 12,954 21.65 
Total 59,831 100.00 
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Description of NCS Sample   
Table 5 reports the description of NCS sample. Approximately 55% of the sample 
is female and 45% male. Eighteen-to-twenty four year olds are underrepresented in the 
sample relative to the U.S. Population (9.5% for both males and female), while the +55 
age group is overrepresented in the sample (34.6% for both males and females) (U.S. 
Census Bureau 2007). Whites are overrepresented while blacks and Hispanics are 
underrepresented. This might indicate that the results of this analysis will be more 
indicative of how advertising affects older white Americans rather than Americans as a 
whole. However, the analysis controls for all of these demographic charactertiscs which 
will help mitigate the affects of using a sample with older and white respondents 
overrepresented.  
 The average number of persons in the respondents household is 3.25. The 
majority of the sample is married (64.95%) and the sample is almost evenly split by 
Census region with the outliers being the South (28.05%) and the West (21.65%).  
Higher educated and higher income people are also overrepresented. College 
graduates make up 32.68% of the sample while non-college grads make up 67% (less 
than HS 12.27%; HS graduate 26.85%; some college 27.75%). Approximately 45% of 
the sample makes more than $87,501 and only 14% make less than $32,500. Employed 
individuals make up 65.11% of the sample.  
There are several ad exposure disparities by demographic group (table six). 
Approximately 61% of men are in the middle exposure group (0<ad exposure<=178) 
while only 49% of women are in that bracket. This is a significant difference with a chi-
square statistic of 906.9 and p<.001. Over 40% of women are in the high exposure group 
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and only 27% of men are in the high exposure group (>178 ad exposure) (significantly 
different with p<.001). As for race, the most black respondents report being in the highest 
exposure group (51.26%) and Hispanics have 50.91% in the low exposure group with 
about 25% in each of the zero exposure and high exposure groups. There are slight 
disparities in education with 40.87% of HS graduates in the high exposure bracket and 
only 31.34% of people without HS degrees and 31.23% of college graduates in the high 
exposure brackets. Those three education brackets are significantly different with a 
p<.001.  There was also a disparity when it came to the size of the family. The mean 
family size of a respondent with 0 ad exposure was 4.2 while the mean family size of a 
respondent with high ad exposure was 3.04 (significantly different with p<.001). This 
could be because as the size of the family increases, there are more people to take care of 
and less time to watch television.  
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Table 6: Number of NCS Respondents by Ad Exposure Bracket 
 
No Ad Exposure 0 to the Mean (178) Ad 
Exposure 
Greater than the Mean 
(178) Ad Exposure 
 Freq Percent Freq Percent Freq Percent 
Gender:       
Male 2,868 10.70 16,522 61.64 7,416 27.67 
Female 2,583 7.82 16,286 49.31 14,156 42.86 
Age:       
18-24 759 12.59 3,304 54.82 1,964 32.59 
25-34 1,249 13.70 4,803 52.68 3,066 33.63 
35-44 1,214 9.78 7,068 56.93 4,133 33.29 
45-54 1,044 8.33 7,092 56.58 4,399 35.09 
55+ 1,185 6.00 10,541 53.41 8,010 40.59 
Race:       
White 2,357 5.46 24,452 56.60 16,393 37.95 
Black 229 5.81 1,692 42.93 2,020 51.26 
Hispanic 2,461 25.13 4,985 50.91 2,346 23.96 
Other 404 13.95 1,679 57.98 813 28.07 
Education:       
Less than HS 1,551 21.12 3,491 47.54 2,301 31.34 
HS Grad 1,297 8.07 8,201 51.06 6,565 40.87 
Some College 1,020 6.14 9,021 54.34 6,560 39.52 
College Grad 1,456 7.45 11,990 61.32 6,106 31.23 
Income:       
< $32,500 1,203 14.90 3,770 46.68 3,103 38.42 
$32,501 - $55,000 1,099 10.33 5,505 51.76 4,032 37.91 
$55,001 - $87,500 1,141 8.39 7,332 53.92 5,126 37.69 
$87,501 - $125,000 1,402 7.22 11,286 58.10 6,738 34.69 
> $125,001 606 7.49 4,915 60.72 2,573 31.79 
Married Status:       
Single 1,236 10.83 6,071 53.21 4,102 35.95 
Married 3,467 8.92 22,015 56.66 13,376 34.42 
Divorce/Separated/Widowed 637 7.05 4,472 49.47 3,931 43.48 
Size of Family:       
1 310 .52 2,722 4.55 2,444 4.08 
2 1,004 1.68 11,154 18.64 7,662 12.81 
3 934 1.56 6,509 10.88 4,276 7.15 
4 1,118 1.87 6,426 10.74 3,815 6.38 
5+ 796 1.33 3,175 5.31 1,934 3.23 
Employment Status:       
Not Employed 1,608 7.70 10,290 49.30 8,976 43.00 
Employed 3,843 9.86 22,518 57.80 12,596 32.33 
Census Region:       
Northeast 1,165 7.77 7,850 52.39 5,969 39.84 
South 1,576 9.39 9,566 57.00 5,639 33.60 
Midwest 1,090 7.21 8,388 55.51 5,634 37.28 
West 1,620 12.51 7,004 54.07 4,330 33.43 
Total 5,451 9.11 32,808 54.83 21,572 36.05 
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Ad exposure does not differ as much with all demographic groups. Age is one of 
these categories with about 10% of each age group in the no exposure bracket, about 55% 
of each age group in the middle exposure bracket, and about 35% of each age group in 
the high exposure bracket. Similar breakdowns are found in income, marital status, and 
Census region. 
Table 7 reports the rate of OTC weight loss pill use (past 12 months), dieting (past 
12 months), and exercising (at least once a week) by demographic group. Approximately 
5% of females report using an OTC weight loss pill while only about 2% of men do. This 
falls in the middle of the range of pill use that other studies have found (Levy et al. 2004; 
Kruger et al. 2003). The difference between gender and pill use is significantly different 
with the chi square statistic of 400.2 and p<.001. Many more women (31.94%) report 
controlling their diet in the past 12 months than do men (significantly different with 
p<.001). A significantly higher percentage of women than men report exercising (p<.001).  
The different age groups have significantly different rates of OTC weight loss pill use 
(chi-square statistic of 218.3 and p<.001). Dieting increases with age (18-24: 16.51%; 
>55: 28.69%) and exercising once a week decreases with age (18-24: 64.13%;  >55: 
49.25%). Dieting and exercising are both significantly different between age brackets 
with p values of less than <.001. While the use of an OTC weight loss pill remains 
relatively constant with education and income, the rates of diet and exercise increase with 
education and income (both significantly different with p<.001).  
          There are not huge disparities in all demographic groups. Rates of OTC pill use, 
diet status, and exercise routine do not differ much across race groups. These rates are 
also fairly constant among the employed/not employed, with about 3% of each group 
 44
using an OTC weight loss pill,  about 25% of each group dieting, and about 55% of each 
group exercising once a week. The exception is the other race group. About 2% of the 
other race respondents report using an OTC weight loss pill, 18% report dieting and 57% 
report exercising. Similar trends can be seen across Census region. OTC weight loss pill 
use is similar for single and divorced/separated/widowed individuals (about 4% for each 
group). Diet status and rate of exercise are both significantly different among marital 
status groups (p<.001 for both). 
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Table 7: Proportion of NCS Respondents by Health Outcome 
 
Used an OTC Pill in the 
Past 12 Months 
Controlled Diet in the 
Past 12 Months 
Exercise at Least Once a 
Week 
 Freq Percent Freq Percent Freq Percent 
Gender:       
Male 445 1.66 4,967 18.53 13,766 51.35 
Female 1,515 4.59 10,548 31.94 19,819 60.01 
Age:       
18-24 241 4.00 995 16.51 3,865 64.13 
25-34 400 4.39 2,022 22.18 5,479 60.09 
35-44 486 3.91 3,147 25.35 7,372 59.38 
45-54 407 3.25 3,688 29.42 7,149 57.03 
55+ 426 2.16 5,663 28.69 9,720 49.25 
Race:       
White 1,388 3.21 11,776 27.26 23,416 54.20 
Black 139 3.53 916 23.24 2,152 54.61 
Hispanic 382 3.90 2,287 23.36 5,208 53.19 
Other 51 1.76 536 18.51 1,648 56.91 
Education:       
Less than HS 252 3.43 1,483 20.20 2,912 39.66 
HS Grad 535 3.33 3,857 24.01 7,428 46.24 
Some College 642 3.87 4,511 27.17 9,798 59.02 
College Grad 520 2.66 5,596 28.62 13,353 68.29 
Income:       
< $32,500 269 3.33 1,947 24.11 3,590 44.45 
$32,501 - $55,000 332 3.12 2,590 24.35 5,326 50.08 
$55,001 - $87,500 520 3.82 3,535 25.99 7,439 54.70 
$87,501 - $125,000 583 3.00 5,068 26.09 11,817 60.83 
> $125,001 256 3.16 2,375 29.34 5,413 66.88 
Married Status:       
Single 431 3.78 2,368 20.76 6,932 60.76 
Married 1,160 2.99 10,425 26.83 22,085 56.84 
Divorce/Separated/Widowed 342 3.78 2,552 28.23 4,293 47.49 
Size of Family:       
1 180 3.29 1,566 28.60 2,823 51.55 
2 532 2.68 5,508 27.79 11,169 56.35 
3 414 3.53 2,952 25.19 6,641 56.67 
4 420 3.70 2,896 25.50 6,718 59.14 
5+ 414 3.61 2,593 22.63 6,234 54.41 
Employment Status:       
Not Employed 597 2.86 5,505 26.37 10,877 52.11 
Employed 1,363 3.50 10,010 25.69 22,708 58.29 
Census Region:       
Northeast 448 2.99 3932 26.24 8169 54.52 
South 580 3.46 4465 26.61 9433 56.21 
Midwest 481 3.18 3,835 25.38 8,394 55.55 
West 451 3.48 3,283 25.34 7,589 58.58 
Total 1,960 3.28 15,515 25.93 33,585 56.13 
 46
Table 8: OLS: Number of OTC weight loss product television ads exposed to 
 
 Coef. Std. Err. P>z 
    
Gender (vs. male):    
Female 18.1402 1.4093 0.000 
Age (vs. 55+):    
18-24 -1.2957 3.2650 0.691 
25-34 5.6861 2.4599 0.021 
35-44 5.0100 2.1623 0.021 
45-54 0.6379 2.0312 0.753 
Race (vs. white):    
Black 39.3920 2.7814 0.000 
Hispanic -4.0190 2.1845 0.066 
Other 3.1332 3.1324 0.317 
Education (vs. HS Degree)    
Less Than HS -1.7615 2.3229 0.448 
Some College -13.5877 1.7955 0.000 
 4 Year College Degree -20.1447 1.8347 0.000 
Income (vs. <$32,500):           
                                $32,501 -$55,000 -7.2488 2.4011 0.003 
$55,001 - $87,500 -9.8421 2.3889 0.000 
$87,501 - $125,000 -8.7944 2.4055 0.000 
> $125,001 -7.8964 2.8728 0.006 
Marital Status (vs. married):    
Single 7.2958 2.1284 0.001 
Divorced/Separated/Widowed 7.9541 1.9750 0.000 
Family Size:    
Number of Individuals in Household 1.5378 0.4607 0.001 
Employment Status (vs. unemployed):   
Employed -5.1766 1.5865 0.001 
Cenus Region (vs. Northeast):    
Midwest -16.5108 1.8483 0.000 
South -25.9159 1.8047 0.000 
West -12.5382 1.9536 0.000 
 R-squared 0.4992 
Observations 59,831 
Television Category Dummies included 
Television Viewing Intensity included 
Simmons Wave Dummies included 
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Regression Analysis  
Model 1: Targeting Model 
 In order to see how advertisers target advertising towards different groups, an 
OLS model was run to look at who is exposed to these ads (Table Eight). Women are 
exposed to, on average, about 18 more ads than men. African American respondents are 
exposed to about 39 more ads than white respondents and Hispanic respondents are 
exposed to about 4 fewer ads than white respondents. There are also large education 
disparities with those who have some college being exposed to about 14 fewer ads and 
those who have graduated college have are exposed to about 20 fewer ads than those who 
have a high school degree. There is no significant difference between those who have a 
high school degree and those who do not. It seems that marketers believe college 
graduates will be more skeptical of these ads and thus they target fewer ads to them but 
no difference between highs school graduates and drop outs.  All income groups are 
exposed to 7 to ten fewer ads than those who make less than $32,500. Single and 
divorced/separated/widowed people are both exposed to about 7 more ads than those who 
are married and with each additional household member ad exposure increased by 1.5. In 
addition, all geographic areas are exposed to fewer ads than those who live in the North 
East. In summary, marketers appear to target women, African Americas, those with less 
education and income, non-married people, and those in the North East.  
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Table 9: Logit: Respondent reports using a diet pill in the past 12 months 
 Female Male 
 Coef. 
Odds 
ratio 
Std. 
Err. P>z Coef. 
Odds 
ratio 
Std. 
Err. P>z 
         
TV Ad Exposure (vs. 0 exposure):         
1 to mean number (178) of OTC 
weight loss ads 0.2682 1.3076 0.1591 0.092 -0.1869 0.8295 0.2337 0.424 
>mean number (178) of OTC weight 
loss ads 0.5262 1.6924 0.1774 0.003 -0.1259 0.8817 0.2756 0.648 
Age (vs. 55+):         
18-24 0.7023 2.0185 0.1296 0.000 -0.2070 0.8130 0.2520 0.411 
25-34 0.7350 2.0855 0.1027 0.000 0.4114 1.5089 0.1762 0.020 
35-44 0.6853 1.9844 0.0930 0.000 0.0968 1.1016 0.1635 0.554 
45-54 0.4632 1.5892 0.0905 0.000 0.0399 1.0407 0.1560 0.798 
Race (vs. white):         
Black -0.1688 0.8446 0.1099 0.124 0.0041 1.0041 0.2047 0.984 
Hispanic 0.0164 1.0165 0.0839 0.845 0.0403 1.0411 0.1493 0.787 
Other -0.7484 0.4731 0.1768 0.000 -0.2389 0.7875 0.2646 0.367 
Education (vs. HS Degree)         
Less Than HS 0.1135 1.1201 0.0956 0.235 0.1913 1.2108 0.1590 0.229 
Some College 0.0413 1.0422 0.0700 0.555 0.1982 1.2192 0.1296 0.126 
 4 Year College Degree -0.1284 0.8795 0.0775 0.097 -0.2199 0.8026 0.1435 0.125 
Income (vs. <$32,500):                
                                $32,501 - 
$55,000 -0.0360 0.9647 0.0983 0.715 -0.0381 0.9626 0.1805 0.833 
$55,001 - $87,500 0.2380 1.2687 0.0947 0.012 0.0462 1.0473 0.1759 0.793 
$87,501 - $125,000 -0.0243 0.9760 0.0992 0.806 -0.0228 0.9775 0.1784 0.898 
> $125,001 0.1527 1.1649 0.1174 0.193 0.0883 1.0923 0.2150 0.681 
Marital Status (vs. married):         
Single -0.0584 0.9433 0.0833 0.483 0.0573 1.0590 0.1452 0.693 
Divorced/Separated/Widowed 0.2319 1.2610 0.0756 0.002 0.2127 1.2371 0.1576 0.177 
Family Size:         
Number of Individuals in Household 0.0072 1.0073 0.0180 0.688 -0.0722 0.9304 0.0345 0.037 
Employment Status (vs. 
unemployed):         
Employed 0.2462 1.2791 0.0631 0.000 0.2744 1.3158 0.1362 0.044 
Census Region (vs. Northeast):         
Midwest 0.1407 1.1511 0.0779 0.071 -0.2417 0.7853 0.1404 0.085 
South 0.1979 1.2188 0.0753 0.009 -0.1117 0.8943 0.1320 0.397 
West 0.2170 1.2424 0.0813 0.008 0.0069 1.0069 0.1397 0.961 
Pseudo R-squared 0.0478 0.0416 
Observations 33,025 26,806 
Television Category Dummies included included 
Television Viewing Intensity included included 
Simmons Wave Dummies included included 
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Table 10: Logit: Respondent reports controlling their diet in the past 12 months 
 Female Male 
 Coef. 
Odds 
ratio 
Std. 
Err. P>z Coef. 
Odds 
ratio 
Std. 
Err. P>z 
         
TV Ad Exposure (vs. 0 exposure):         
1 to mean number (178) of OTC 
weight loss ads 0.0807 1.0841 0.0631 0.201 0.1095 1.1157 0.0752 0.146 
>mean number (178) of OTC weight 
loss ads 0.1570 1.1699 0.0728 0.031 0.1926 1.2124 0.0900 0.032 
Age (vs. 55+):         
18-24 -0.6012 0.5481 0.0640 0.000 -0.9340 0.3930 0.0937 0.000 
25-34 -0.2892 0.7488 0.0466 0.000 -0.6002 0.5487 0.0652 0.000 
35-44 -0.1401 0.8693 0.0406 0.001 -0.3548 0.7013 0.0539 0.000 
45-54 0.0164 1.0165 0.0373 0.660 -0.1392 0.8701 0.0486 0.004 
Race (vs. white):         
Black -0.2270 0.7969 0.0525 0.000 -0.0888 0.9150 0.0747 0.234 
Hispanic -0.1542 0.8571 0.0416 0.000 0.0339 1.0345 0.0547 0.535 
Other -0.4903 0.6124 0.0651 0.000 -0.2995 0.7412 0.0860 0.000 
Education (vs. HS Degree)         
Less Than HS -0.1556 0.8559 0.0469 0.001 -0.0109 0.9891 0.0605 0.857 
Some College 0.1980 1.2190 0.0332 0.000 0.2451 1.2778 0.0472 0.000 
 4 Year College Degree 0.2378 1.2685 0.0345 0.000 0.3425 1.4085 0.0466 0.000 
Income (vs. <$32,500):                
                                $32,501 - 
$55,000 0.0795 1.0827 0.0445 0.074 -0.0857 0.9179 0.0647 0.185 
$55,001 - $87,500 0.2089 1.2323 0.0445 0.000 -0.0083 0.9918 0.0632 0.896 
$87,501 - $125,000 0.2026 1.2246 0.0453 0.000 0.0343 1.0349 0.0634 0.588 
> $125,001 0.3577 1.4300 0.0538 0.000 0.2135 1.2380 0.0733 0.004 
Marital Status (vs. married):         
Single -0.0378 0.9629 0.0408 0.354 -0.0867 0.9169 0.0564 0.124 
Divorced/Separated/Widowed -0.0586 0.9431 0.0343 0.087 -0.0020 0.9980 0.0560 0.971 
Family Size:         
Number of Individuals in Household -0.0349 0.9657 0.0089 0.000 -0.0441 0.9569 0.0121 0.000 
Employment Status (vs. 
unemployed):         
Employed 0.1315 1.1405 0.0284 0.000 0.0385 1.0392 0.0439 0.381 
Census Region (vs. Northeast):         
Midwest -0.0602 0.9416 0.0347 0.083 0.0144 1.0145 0.0463 0.756 
South 0.0008 1.0008 0.0337 0.982 0.0506 1.0519 0.0450 0.261 
West 0.0407 1.0415 0.0366 0.267 -0.0125 0.9876 0.0492 0.800 
Pseudo R-squared 0.0533 0.0631 
Observations 33,025 26,806 
Television Category Dummies included included 
Television Viewing Intensity included included 
Simmons Wave Dummies included included 
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Table 11: Logit: Respondent reports exercising at least once a week 
 Female Male 
 Coef. 
Odds 
ratio 
Std. 
Err. P>z Coef. 
Odds 
ratio 
Std. 
Err. P>z 
         
TV Ad Exposure (vs. 0 exposure):         
1 to mean number (178) of OTC 
weight loss ads 0.1951 1.2155 0.0550 0.000 0.1540 1.2565 0.0530 0.004 
>mean number (178) of OTC weight 
loss ads 0.1713 1.1868 0.0647 0.008 0.1338 1.1432 0.0661 0.043 
Age (vs. 55+):         
18-24 0.3137 1.3684 0.0566 0.000 0.3200 1.3771 0.0642 0.000 
25-34 0.1912 1.2107 0.0429 0.000 0.1740 1.1900 0.0487 0.000 
35-44 0.2255 1.2529 0.0378 0.000 0.1328 1.1420 0.0424 0.002 
45-54 0.0947 1.0993 0.0354 0.007 -0.0441 0.9568 0.0397 0.266 
Race (vs. white):         
Black -0.2860 0.7513 0.0474 0.000 -0.2326 0.7925 0.0558 0.000 
Hispanic -0.1072 0.8983 0.0382 0.005 0.0739 1.0767 0.0421 0.079 
Other -0.2294 0.7950 0.0551 0.000 -0.1487 0.8618 0.0598 0.013 
Education (vs. HS Degree)         
Less Than HS -0.2900 0.7482 0.0419 0.000 -0.1470 0.8633 0.0440 0.001 
Some College 0.3095 1.3627 0.0303 0.000 0.3187 1.3753 0.0350 0.000 
 4 Year College Degree 0.6121 1.8442 0.0319 0.000 0.7262 2.0673 0.0357 0.000 
Income (vs. <$32,500):                
                                $32,501 - 
$55,000 0.0814 1.0848 0.0401 0.043 0.0491 1.0504 0.0491 0.317 
$55,001 - $87,500 0.1374 1.1473 0.0404 0.001 0.1200 1.1275 0.0483 0.013 
$87,501 - $125,000 0.2129 1.2372 0.0410 0.000 0.1458 1.1570 0.0483 0.003 
> $125,001 0.3490 1.4177 0.0497 0.000 0.3352 1.3982 0.0572 0.000 
Marital Status (vs. married):         
Single 0.0505 1.0517 0.0374 0.178 0.0455 1.0466 0.0413 0.270 
Divorced/Separated/Widowed -0.1594 0.8526 0.0317 0.000 0.0102 1.0103 0.0445 0.818 
Family Size:         
Number of Individuals in Household -0.0688 0.9335 0.0081 0.000 -0.0574 0.9443 0.0089 0.000 
Employment Status (vs. 
unemployed):         
Employed -0.1108 0.8951 0.0262 0.000 -0.0908 0.9132 0.0340 0.008 
Census Region (vs. Northeast):         
Midwest 0.0603 1.0621 0.0321 0.061 0.0147 1.0148 0.0357 0.680 
South -0.0165 0.9837 0.0313 0.599 -0.0518 0.9495 0.0351 0.140 
West 0.1450 1.1560 0.0340 0.000 0.1409 1.1513 0.0378 0.000 
Pseudo R-squared 0.0394 0.0372 
Observations 33,025 26,806 
Television Category Dummies included included 
Television Viewing Intensity included included 
Simmons Wave Dummies included included 
 
 
 51
Table 12: Logit: Respondent reports controlling their diet in the past 12 months and 
exercising at least once a week 
 
 Female Male 
 Coef. 
Odds 
ratio 
Std. 
Err. P>z Coef. 
Odds 
ratio 
Std. 
Err. P>z 
TV Ad Exposure (vs. 0 exposure):         
1 to mean number (178) of OTC 
weight loss ads 0.1634 1.1775 0.0777 0.035 0.1988 1.2199 0.0966 0.040 
>mean number (178) of OTC 
weight loss ads 0.2289 1.2572 0.0884 0.010 0.3009 1.3511 0.1130 0.008 
Age (vs. 55+):         
18-24 -0.2699 0.7635 0.0752 0.000 -0.8277 0.4370 0.1156 0.000 
25-34 -0.1017 0.9033 0.0547 0.063 -0.4503 0.6374 0.0781 0.000 
35-44 0.0248 1.0251 0.0475 0.601 -0.3194 0.7266 0.0652 0.000 
45-54 0.0706 1.0732 0.0436 0.105 -0.1656 0.8474 0.0584 0.005 
Race (vs. white):         
Black -0.3357 0.7148 0.0652 0.000 -0.1895 0.8273 0.0952 0.047 
Hispanic -0.1922 0.8251 0.0497 0.000 0.0450 1.0460 0.0671 0.502 
Other  -0.4516 0.6366 0.0759 0.000 -0.3453 0.7080 0.1047 0.001 
Education (vs. HS Degree)         
Less Than HS -0.3123 0.7318 0.0624 0.000 -0.1226 0.8846 0.0822 0.136 
Some College  0.3015 1.3519 0.0394 0.000 0.4243 1.5284 0.0588 0.000 
 4 Year College Degree 0.4395 1.5520 0.0402 0.000 0.6029 1.8274 0.0574 0.000 
Income (vs. <$32,500):                
  $32,501 - $55,000 0.1578 1.1709 0.0558 0.005 -0.0794 0.9237 0.0832 0.340 
$55,001 - $87,500 0.3405 1.4056 0.0549 0.000 0.0745 1.0773 0.0798 0.351 
$87,501 - $125,000 0.3863 1.4715 0.0556 0.000 0.1711 1.1866 0.0797 0.032 
> $125,001 0.5593 1.7495 0.0640 0.000 0.3445 1.4112 0.0902 0.000 
Marital Status (vs. married):         
Single 0.0208 1.0210 0.0474 0.661 -0.0373 0.9634 0.0683 0.585 
Divorced/Separated/Widowed -0.1042 0.9011 0.0411 0.011 0.0192 1.0194 0.0678 0.777 
Family Size:         
Number of Individuals in 
Household -0.0662 0.9360 0.0109 0.000 -0.0613 0.9405 0.0151 0.000 
Employment Status (vs. 
unemployed):         
Employed 0.0389 1.0396 0.0333 0.243 -0.0248 0.9755 0.0528 0.639 
Census Region (vs. Northeast):         
Midwest -0.0407 0.9601 0.0405 0.315 0.0485 1.0497 0.0554 0.381 
South -0.0390 0.9617 0.0394 0.322 -0.0009 0.9991 0.0543 0.986 
West 0.0796 1.0828 0.0424 0.061 0.0043 1.0043 0.0590 0.942 
Pseudo R-squared 0.0513 0.0617 
Observations 33,025 26,806 
Television Category Dummies included included 
Television Viewing Intensity included included 
Simmons Wave Dummies included included 
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Analysis of Ad Exposure 
Model 2: Respondent reports using OTC weight loss pill 
 Controlling for all of the targeting controls identified in model one, large effects 
of ad exposure can be seen in the female model (Table Nine). Females are 31% (p=.092) 
more likely to use an OTC weight loss pill if they are exposed to between 1 to 178 ads 
(the mean) and 69% (p=.003) more likely to use such a product if they see greater than 
178 ads.  There are no such significant effects for men (low exposure- p=.424; high 
exposure- p=.648). The differences between the male and female coefficients are 
significantly different (p<.001) which is suggestive of gender differences in the impact of 
these advertisements. 
Model 3: Respondent reports controlling diet  
 In addition to predicting use of an OTC weight loss product, ad exposure also   
impacts the respondents diet status when targeting controls are included. In this model, 
as shown in Table Ten, only high ad exposure (>178) predicted that the respondent was 
controlling their diet in the past 12 months. Females were 17% more likely to control 
their diet if they had been exposed to more than 178 ads (p=.031) while men were 21% 
more likely to control their diet if they had been exposed to more than 178 ads. Just like 
model two, the high exposure coefficient between males and females was significantly 
different. 
Model 4: Respondent reports exercising at least once a week  
 Unlike use of an OTC weight control product and diet status, there are few gender 
differences when it comes to exercising once a week, as seen in Table Eleven (when all 
other targeting effects are controlled for). Low ad exposure (1 to 178 ads) makes females 
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22% more likely to exercise once a week and males 25% more likely. High ad exposure 
(more than 178 ads) has a smaller effect; 19% for females and 14% for males 
(significantly different at p<.001).  
 
Model 5: Respondent reports controlling diet in the past 12 months and exercising at 
least once a week  
 Just as ad exposure affected diet and exercise routines in males and females 
differently, the effect of ad exposure on the combination of diet and exercise also differs 
by gender (Table Twelve). When exposure is between 1 and 178 ads, females are 18% 
more likely to diet and exercise while males are slightly more likely (22%). Large 
amounts of ad exposure (>178) make females 26% more likely to use diet and exercise in 
conjunction while males are even more inclined (35%). This reaffirms the positive spill 
over effects of ad exposure. Both men and women are significantly more likely to use the 
expert recommended diet and exercise (in conjunction) when exposed to advertising for 
OTC weight loss product advertising (both low and high ad exposure). The coefficients 
were significantly different for males and females (p<.001) which suggests that the 
spillover effects affect males more than females.  
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Table 13: Summary Regression Table 
 Pills Diet 
 Odds ratio Odds ratio 
TV Ad Exposure (vs. 0 
exposure): Female  Male  Female  Male  
1 to mean number (178) of 
OTC weight loss ads 1.3076 ** 0.8295  1.0841  1.1157  
>mean number (178) of OTC 
weight loss ads 1.6924 *** 0.8817  1.1699 ** 1.2124 ** 
         
 Exercise Diet and exercise 
 Odds ratio Odds ratio 
TV Ad Exposure (vs. 0 
exposure): Female  Male  Female  Male  
1 to mean number (178) of 
OTC weight loss ads 1.2155 *** 1.2565 *** 1.1775 ** 1.2199 ** 
>mean number (178) of OTC 
weight loss ads 1.1868 *** 1.1432 ** 1.2572 *** 1.3511 *** 
* significant < 10%; ** significant < 5%; *** significant < 1%    
 
Summary  
 In summary, ad exposure is very predictive of all five outcomes measured (table 
13). Women with high ad exposure are 76% more likely to use all three of the methods. 
Females with low ad exposure are 30% and 22% more likely to use OTC weight loss 
products and exercise once a week, respectively. Alternatively, men with low ad 
exposure are only more likely to exercise once a week (17%). High ad exposure is 
significantly predictive of use of an OTC weight loss product, starting a diet, and 
exercising once a week for women. High ad exposure is significantly predictive for only 
starting a diet and exercising once a week when it comes to men. Lastly, ad exposure is 
significantly predictive of using diet in conjunction with exercise for both men and 
women with both low and high ad exposure. Males and females are affected significantly 
differently by exposure to these ads.  
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 The models used in this analysis use a very robust design in determining the effect 
of advertising exposure on the consumer. Separating the sample by gender allows the 
analysis to look at men and women differently, which is warranted by the different levels 
of overweight and obesity by gender. The demographic controls mimic those used by 
marketers in their targeting behavior. The television controls (viewing intensity and 
television categories) help isolate the effect of the advertising on the consumer by 
controlling for the variance associated with viewing different types of television 
programs (categories) or viewing television frequently (the viewing intensity variable).  
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VIII. Discussion and Conclusions 
As evidenced by their report in 2002 and their set of industry guidelines released 
in 2003, the FTC is concerned about the impact of claims made in OTC weight loss 
product advertising on the consumer. A large percent of Americans are overweight and 
obese (Ogden et al. 2006) and medical experts are in agreement that the best method for 
reducing body mass is a reduced calorie diet in combination with regular physical activity 
(Miller et al. 1997). Despite the proven efficacy of reduced caloric intake combined with 
increased physical activity, the market has responded to the obesity epidemic with a 
plethora of OTC weight loss products promising quick and easy results, but these 
products have little proven efficacy and no demonstrated record of safety.  
In this study I investigate the question whether weight loss ads are effective in 
encouraging consumers use of commercial weight loss products and, furthermore, if 
these ads might be raising awareness about obesity and its consequences that could 
possibly have positive spillover effects by encouraging consumers to engage in other 
obesity-reduction behaviors such as diet and exercise. The individual-level data set used 
in this analysis (NCS) is the same commercial data used by marketers in their ad 
targeting and media planning behavior. The data provide detailed information on the 
consumers demographic characteristics, their media (TV) watching behavior, and their 
product purchases. Marketers use these data to define and target their ad campaigns. By 
using these identical commercial data I have the same information that marketers use in 
their targeting behavior. Im able to control for variables in the analysis that would 
account for greater or lesser exposure to weight loss ads based purely on target market 
characteristics.  I examine whether greater exposure to these weight loss ads is correlated 
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with greater use of weight loss products and other obesity-reduction behaviors such as 
diet and exercise.      
In the first regression I examine the characteristics of marketers targeting 
behavior by regressing demographic characteristics of the consumer and characteristics of 
their media watching behavior on number of weight loss ads to which they are exposed. 
Result indicate that females are exposed to 18 more OTC weight loss television ads on 
average than males, and that controlling for amount of televisions watched and type of 
shows viewed, black respondents are exposed to, on average, 40 more ads than white 
respondents. Although there were other significant effects none of them were as striking 
as the effects of gender and race. 
Based on results from the first regression and previous research reported in the 
front section of this thesis, it became clear that not only are obesity rates significantly 
different in the male and female population, but so are their respective exposure to weight 
loss ads and their obesity-related behavior, indicating that the underlying relationship of 
interest in the subsequent regressions also might be different. For this reason I decided to 
split the data into a male and female sample for the subsequent regressions.         
In the models examining the impact of exposure to weight loss ads on the 
consumption of weight loss product results indicate that, controlling for targeting effects 
and amount of television viewed, exposure to both low and high levels of weight loss ads 
is correlated with an increased likelihood of using an OTC weight loss pill for women, 
but not for men, and in increased likelihood of both men and women starting a diet, 
exercising once a week, or doing both. These results are suggestive of possible positive 
spillover effects of OTC weight loss product ads on other diet-related behavior of 
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consumers.  Avery et al. (2007) found similar positive spillover effects of commercial 
advertising. They found that OTC smoking cessation print advertisements increased the 
likelihood of all types of quitting behavior, including attempts without the use of the 
advertised product.  
One possible explanation for these results is that these ads are having a wake-up 
effect on consumers, reminding them of the consequences of obesity or rewards for 
weight loss, regardless of the method used to attain that reduced weight. Since results 
indicate that women rather than men are more likely to respond to these ads by taking a 
pill it could be that there is a social stigma surrounding the use of weight loss products by 
men, that men are simply less likely to use market-based interventions related to their 
health, or that men resort to self controllable methods of weight loss.  Other research 
supports these hypotheses. Research has found that men are less likely to visit a doctor 
then women (Williams 2003), but more likely than women to engage in leisure time 
physical activity (Adler et al. 1993). On the other hand, women who are balancing work 
and family priorities might be more susceptible to the promises offered in OTC weight 
loss ads of a quick fix to the problem of overweight, or the easier self-control method of 
reducing calories rather than the more time consuming activity of scheduling workout 
time at the gym.  
In summary, results of the analyses reported above indicate a significant 
correlation between commercial OTC weight loss product television advertising exposure 
and weight-reducing behaviors of consumers. While every attempt was made to control 
for factors known to be used by marketers in their media targeting behavior, the impact of 
these effects cant be totally ruled out as an alternative explanation for the results of this 
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study. Future research should more fully examine targeting and how ad exposure differs 
across demographic groups. 
A public policy concern still remains regarding the reported deceptiveness of 
OTC weight loss product advertising and the lack of evidence on the efficacy of most of 
these products. Products purchased that do not deliver on their promised effects represent 
significant consumer welfare loss and inefficiency in the market. Cleland, Gross, Koss et 
al. (2002) concluded that OTC weight loss advertising was extremely deceptive and 
suggested that greater market regulation be implemented in this industry. While this 
study did not examine the content and level of deceptiveness of OTC weight loss product 
ads, results do indicate that a blanket ban on these ads by the FTC could possibly 
eliminate the positive spillover effects of encouraging other weight loss behaviors. Future 
research in this areas is needed to examine the level of deceptiveness in television weight 
loss advertisements, and how different levels of deception impact diet-related behaviors. 
It might also be beneficial to examine deceptiveness by brand which could streamline 
regulatory efforts to control deception. Further research also should examine the 
combined impact of print and television weigh loss advertising on these same weight loss 
behaviors since marketing research has indicated that these two types of media tend to 
have a synergistic impact (Confer 1992; Confer and McGlathery 1991; Naik and Raman 
2003; Smith 1991).  
Like any analysis, this study was not without its limitations. The first limitation 
was the exposure measure itself. Although the ad-matching algorithm uses television 
show viewing frequency to approximate probabilities of ad exposure, there is no way to 
know that respondents actually watched the ads they were exposed to. It is possible that 
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they were engaging in another activity during the commercial break or simply not paying 
attention. With the rise of TiVo and DVR, respondents could have zapped through 
these ads. Secondly, the ad matching algorithm assumes that respondents correctly recall 
which shows they watch and how often. In a list of over 400 shows, the ability to 
accurately recall viewing behavior could come into question. A second limitation in this 
study is the issue of targeting. The demographic characteristics and television viewing 
variables were used to control for targeting effects, but it is possible that some still exist 
and that the results found in this study are the result of targeting and not the hypothesized 
effects.  
Dealing with a complex problem like the overweight and obesity epidemic is 
going to take complex solutions. As schools ban fast food from cafeterias and health 
insurance companies give credits for those who join gyms, innovative solutions to the 
overweight and obesity epidemic are rising. Although OTC weight loss products do not 
have a proven record of safety and efficacy, their advertising may be helping consumers 
wake-up and chose healthy methods to achieve their weight loss goals.  
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 X. Appendices 
Appendix 1:  21 U.S.C. 321 §2-13 
§2. Findings. 
Congress finds that - 
• (1) improving the health status of United States citizens ranks at the top of the national 
priorities of the Federal Government; 
• (2) the importance of nutrition and the benefits of dietary supplements to health 
promotion and disease prevention have been documented increasingly in scientific 
studies; 
• (3)(A) there is a link between the ingestion of certain nutrients or dietary supplements 
and the prevention of chronic diseases such as cancer, heart disease, and osteoporosis; 
and 
• (B) clinical research has shown that several chronic diseases can be prevented simply 
with a healthful diet, such as a diet that is low in fat, saturated fat, cholesterol, and 
sodium, with a high proportion of plant-based foods; 
• (4) healthful diets may mitigate the need for expensive medical procedures, such as 
coronary bypass surgery or angioplasty; 
• (5) preventive health measures, including education, good nutrition, and appropriate use 
of safe nutritional supplements will limit the incidence of chronic diseases, and reduce 
long-term health care expenditures; 
• (6)(A) promotion of good health and healthy lifestyles improves and extends lives while 
reducing health care expenditures; and 
• (B) reduction in health care expenditures is of paramount importance to the future of the 
country and the economic well-being of the country; 
• (7) there is a growing need for emphasis on the dissemination of information linking 
nutrition and long-term good health; 
• (8) consumers should be empowered to make choices about preventive health care 
programs based on data from scientific studies of health benefits related to particular 
dietary supplements; 
• (9) national surveys have revealed that almost 50 percent of the 260,000,000 Americans 
regularly consume dietary supplements of vitamins, minerals, or herbs as a means of 
improving their nutrition; 
• (10) studies indicate that consumers are placing increased reliance on the use of 
nontraditional health care providers to avoid the excessive costs of traditional medical 
services and to obtain more holistic consideration of their needs; 
• (11) the United States will spend over $1,000,000,000,000 on health care in 1994, which 
is about 12 percent of the Gross National Product of the United States, and this amount 
and percentage will continue to increase unless significant efforts are undertaken to 
reverse the increase; 
• (12)(A) the nutritional supplement industry is an integral part of the economy of the 
United States; 
• (B) the industry consistently projects a positive trade balance; and 
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• (C) the estimated 600 dietary supplement manufacturers in the United States produce 
approximately 4,000 products, with total annual sales of such products alone reaching at 
least $4,000,000,000; 
• (13) although the Federal Government should take swift action against products that are 
unsafe or adulterated, the Federal Government should not take any actions to impose 
unreasonable regulatory barriers limiting or slowing the flow of safe products and 
accurate information to consumers; 
• (14) dietary supplements are safe within a broad range of intake, and safety problems 
with the supplements are relatively rare; and 
• (15)(A) legislative action that protects the right of access of consumers to safe dietary 
supplements is necessary in order to promote wellness; and 
• (B) a rational Federal framework must be established to supersede the current ad hoc, 
patchwork regulatory policy on dietary supplements. 
§3. Definitions. 
• (a) Definition of Certain Foods as Dietary Supplements. Section 201 (21 U.S.C. 321) 
is amended by adding at the end the following: 
"(ff) The term "dietary supplement" -  
o "(1) means a product (other than tobacco) intended to supplement the diet that 
bears or contains one or more of the following dietary ingredients: 
! "(A) a vitamin; 
! "(B) a mineral; 
! "(C) an herb or other botanical; 
! "(D) an amino acid; 
! "(E) a dietary substance for use by man to supplement the diet by 
increasing the total dietary intake; or 
! "(F) a concentrate, metabolite, constituent, extract, or combination of any 
ingredient described in clause (A), (B), (C), (D), or (E); 
o "(2) means a product that - 
! "(A)(i) is intended for ingestion in a form described in section 
411(c)(1)(B)(i); or 
! "(ii) complies with section 411(c)(1)(B)(ii); 
! "(B) is not represented for use as a conventional food or as a sole item of a 
meal or the diet; and 
! "(C) is labeled as a dietary supplement; and 
o "(3) does - 
! "(A) include an article that is approved as a new drug under section 505, 
certified as an antibiotic under section 507, or licensed as a biologic under 
section 351 of the Public Health Service Act (42 U.S.C. 262) and was, 
prior to such approval, certification, or license, marketed as a dietary 
supplement or as a food unless the Secretary has issued a regulation, after 
notice and comment, finding that the article, when used as or in a dietary 
supplement under the conditions of use and dosages set forth in the 
labeling for such dietary supplement, is unlawful under section 402(f); and 
! "(B) not include - 
 70
! "(i) an article that is approved as a new drug under section 505, 
certified as an antibiotic under section 507, or licensed as a 
biologic under section 351 of the Public Health Service Act (42 
U.S.C. 262), or 
! "(ii) an article authorized for investigation as a new drug, antibiotic, 
or biological for which substantial clinical investigations have been 
instituted and for which the existence of such investigations has 
been made public, 
which was not before such approval, certification, licensing, or authorization marketed as 
a dietary supplement or as a food unless the Secretary, in the Secretary's discretion, has 
issued a regulation, after notice and comment, finding that the article would be lawful 
under this Act. 
Except for purposes of section 201(g), a dietary supplement shall be deemed to be a food within 
the meaning of this Act.  
• (b) Exclusion from Definition of Food Additive. Section 201(s) (21 U.S.C. 321(s)) is 
amended - 
o (1) by striking "or" at the end of subparagraph (4); 
o (2) by striking the period at the end of subparagraph (5) and inserting "; or"; and 
o (3) by adding at the end the following new subparagraph (6) "an ingredient 
described in paragraph (ff) in, or intended for use in, a dietary supplement.". 
• (c) Form of Ingestion. Section 411(c)(1)(B) (21 U.S.C. 350(c)(1)(B)) is amended - 
o (1) in clause (i), by inserting "powder, softgel, gelcap," after "capsule,"; and 
o (2) in clause (ii), by striking "does not simulate and". 
§4. Safety of Dietary Supplements and Burden of Proof on FDA. 
Section 402 (21 U.S.C. 342) is amended by adding at the end the following: 
• "(f)(1) If it is a dietary supplement or contains a dietary ingredient that - 
o "(A) presents a significant or unreasonable risk of illness or injury under - 
! "(i) conditions of use recommended or suggested in labeling, or 
! "(ii) if no conditions of use are suggested or recommended in the labeling, 
under ordinary conditions of use; 
o "(B) is a new dietary ingredient for which there is inadequate information to 
provide reasonable assurance that such ingredient does not present a significant or 
unreasonable risk of illness or injury; 
o "(C) the Secretary declares to pose an imminent hazard to public health or safety, 
except that the authority to make such declaration shall not be delegated and the 
Secretary shall promptly after such a declaration initiate a proceeding in 
accordance with sections 554 and 556 of title 5, United States Code, to affirm or 
withdraw the declaration; or 
o "(D) is or contains a dietary ingredient that renders it adulterated under paragraph 
(a)(1) under the conditions of use recommended or suggested in the labeling of 
such dietary supplement. 
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In any proceeding under this subparagraph, the United States shall bear the burden of 
proof on each element to show that a dietary supplement is adulterated. The court shall 
decide any issue under this paragraph on a de novo basis.  
• (2) Before the Secretary may report to a United States attorney a violation of paragraph 
(1)(A) for a civil proceeding, the person against whom such proceeding would be 
initiated shall be given appropriate notice and the opportunity to present views, orally and 
in writing, at least 10 days before such notice, with regard to such proceeding. 
§5. Dietary Supplement Claims. 
Chapter IV (21 U.S.C. 341 et seq.) is amended by inserting after section 403A the following new 
section: 
DIETARY SUPPLEMENT LABELING EXEMPTIONS  
• "Sec. 403B. (a) IN GENERAL.- A publication, including an article, a chapter in a book, 
or an official abstract of a peer-reviewed scientific publication that appears in an article 
and was prepared by the author or the editors of the publication, which is reprinted in its 
entirety, shall not be defined as labeling when used in connection with the sale of a 
dietary supplement to consumers when it - 
o "(1) is not false or misleading; 
o "(2) does not promote a particular manufacturer or brand of a dietary supplement; 
o "(3) is displayed or presented, or is displayed or presented with other such items 
on the same subject matter, so as to present a balanced view of the available 
scientific information on a dietary supplement; 
o "(4) if displayed in an establishment, is physically separate from the dietary 
supplements; and 
o "(5) does not have appended to it any information by sticker or any other method. 
• "(b) APPLICATION. - Subsection (a) shall not apply to or restrict a retailer or 
wholesaler of dietary supplements in any way whatsoever in the sale of books or other 
publications as a part of the business of such retailer or wholesaler. 
• "(c) BURDEN OF PROOF. - In any proceeding brought under subsection (a), the 
burden of proof shall be on the United States to establish that an article or other such 
matter is false or misleading.". 
§6. Statements of Nutritional Support. 
Section 403(r) (21 U.S.C. 343(r)) is amended by adding at the end the following: 
• "(6) For purposes of paragraph (r)(1)(B), a statement for a dietary supplement may be 
made if - 
o "(A) the statement claims a benefit related to a classical nutrient deficiency 
disease and discloses the prevalence of such disease in the United States, 
describes the role of a nutrient or dietary ingredient intended to affect the 
structure or function in humans, characterizes the documented mechanism by 
which a nutrient or dietary ingredient acts to maintain such structure or function, 
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or describes general well-being from consumption of a nutrient or dietary 
ingredient, 
o "(B) the manufacturer of the dietary supplement has substantiation that such 
statement is truthful and not misleading, and 
o "(C) the statement contains, prominently displayed and in boldface type, the 
following: "This statement has not been evaluated by the Food and Drug 
Administration. This product is not intended to diagnose, treat, cure, or prevent 
any disease.". 
A statement under this subparagraph may not claim to diagnose, mitigate, treat, cure, or 
prevent a specific disease or class of diseases. If the manufacturer of a dietary supplement 
proposes to make a statement described in the first sentence of this subparagraph in the 
labeling of the dietary supplement, the manufacturer shall notify the Secretary no later 
than 30 days after the first marketing of the dietary supplement with such statement that 
such a statement is being made.".  
§7. Dietary Supplement Ingredient Labeling and Nutrition Information 
Labeling. 
• (a) MISBRANDED SUPPLEMENTS. - Section 403 (21 U.S.C. 343) is amended by 
adding at the end the following: "(s) If - 
o "(1) it is a dietary supplement; and 
o "(2)(A) the label or labeling of the supplement fails to list - 
! "(i) the name of each ingredient of the supplement that is described in 
section 201(ff); and 
! "(ii)(I) the quantity of each such ingredient; or 
! "(II) with respect to a proprietary blend of such ingredients, the total 
quantity of all ingredients in the blend; 
o "(B) the label or labeling of the dietary supplement fails to identify the product by 
using the term `dietary supplement', which term may be modified with the name 
of such an ingredient; 
o "(C) the supplement contains an ingredient described in section 201(ff)(1)(C), and 
the label or labeling of the supplement fails to identify any part of the plant from 
which the ingredient is derived; 
o "(D) the supplement - 
! "(i) is covered by the specifications of an official compendium; 
! "(ii) is represented as conforming to the specifications of an official 
compendium; and 
! "(iii) fails to so conform; or 
o "(E) the supplement - 
! "(i) is not covered by the specifications of an official compendium; and 
! "(ii)(I) fails to have the identity and strength that the supplement is 
represented to have; or 
! "(II) fails to meet the quality (including tablet or capsule disintegration), 
purity, or compositional specifications, based on validated assay or other 
appropriate methods, that the supplement is represented to meet.". 
• (b) Supplement Listing on Nutrition Labeling. Section 403(q)(5)(F) (21 U.S.C. 
343(q)(5)(F)) is amended to read as follows: 
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o "(F) A dietary supplement product (including a food to which section 411 applies) 
shall comply with the requirements of subparagraphs (1) and (2) in a manner 
which is appropriate for the product and which is specified in regulations of the 
Secretary which shall provide that - 
! "(i) nutrition information shall first list those dietary ingredients that are 
present in the product in a significant amount and for which a 
recommendation for daily consumption has been established by the 
Secretary, except that a dietary ingredient shall not be required to be listed 
if it is not present in a significant amount, and shall list any other dietary 
ingredient present and identified as having no such recommendation; 
! "(ii) the listing of dietary ingredients shall include the quantity of each 
such ingredient (or of a proprietary blend of such ingredients) per serving; 
! "(iii) the listing of dietary ingredients may include the source of a dietary 
ingredient; and 
! "(iv) the nutrition information shall immediately precede the ingredient 
information required under subclause (i), except that no ingredient 
identified pursuant to subclause (i) shall be required to be identified a 
second time.". 
• (c) Percentage Level Claims. Section 403(r)(2) (21 U.S.C. 343(r)(2)) is amended by 
adding after clause (E) the following: 
o "(F) Subclause (i) clause (A) does not apply to a statement in the labeling of a 
dietary supplement that characterizes the percentage level of a dietary ingredient 
for which the Secretary has not established a reference daily intake, daily 
recommended value, or other recommendation for daily consumption.". 
• (d) Vitamins and Minerals. Section 411(b)(2) (21 U.S.C. 350(b)(2)) is amended - 
o (1) by striking "vitamins or minerals" and inserting "dietary supplement 
ingredients described in section 201(ff)"; 
o (2) by striking "(2)(A)" and inserting "(2)"; and 
o (3) by striking subparagraph (B). 
• (e) Effective Date. Dietary supplements - 
o (1) may be labeled after the date of the enactment of this Act in accordance with 
the amendments made by this section, and 
o (2) shall be labeled after December 31, 1996, in accordance with such 
amendments. 
§8. New Dietary Ingredients. 
Chapter IV of the Federal Food, Drug, and Cosmetic Act is amended by adding at the end the 
following: 
"NEW DIETARY INGREDIENTS 
• "SEC. 413. (a) IN GENERAL.- A dietary supplement which contains a new dietary 
ingredient shall be deemed adulterated under section 402(f) unless it meets one of the 
following requirements: 
o "(1) The dietary supplement contains only dietary ingredients which have been 
present in the food supply as an article used for food in a form in which the food 
has not been chemically altered. 
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o "(2) There is a history of use or other evidence of safety establishing that the 
dietary ingredient when used under the conditions recommended or suggested in 
the labeling of the dietary supplement will reasonably be expected to be safe and, 
at least 75 days before being introduced or delivered for introduction into 
interstate commerce, the manufacturer or distributor of the dietary ingredient or 
dietary supplement provides the Secretary with information, including any 
citation to published articles, which is the basis on which the manufacturer or 
distributor has concluded that a dietary supplement containing such dietary 
ingredient will reasonably be expected to be safe. 
The Secretary shall keep confidential any information provided under paragraph (2) for 
90 days following its receipt. After the expiration of such 90 days, the Secretary shall 
place such information on public display, except matters in the information which are 
trade secrets or otherwise confidential, commercial information.  
• "(b) PETITION. - Any person may file with the Secretary a petition proposing the 
issuance of an order prescribing the conditions under which a new dietary ingredient 
under its intended conditions of use will reasonably be expected to be safe. The Secretary 
shall make a decision on such petition within 180 days of the date the petition is filed 
with the Secretary. For purposes of chapter 7 of title 5, United States Code, the decision 
of the Secretary shall be considered final agency action. 
• "(c) DEFINITION. - For purposes of this section, the term "new dietary ingredient" 
means a dietary ingredient that was not marketed in the United States before October 15, 
1994 and does not include any dietary ingredient which was marketed in the United 
States before October 15, 1994.". 
§9. Good Manufacturing Practices. 
Section 402 (21 U.S.C. 342), as amended by section 4, is amended by adding at the end the 
following: 
• "(g)(1) If it is a dietary supplement and it has been prepared, packed, or held under 
conditions that do not meet current good manufacturing practice regulations, including 
regulations requiring, when necessary, expiration date labeling, issued by the Secretary 
under subparagraph (2). 
• "(2) The Secretary may by regulation prescribe good manufacturing practices for dietary 
supplements. Such regulations shall be modeled after current good manufacturing 
practice regulations for food and may not impose standards for which there is no current 
and generally available analytical methodology. No standard of current good 
manufacturing practice may be imposed unless such standard is included in a regulation 
promulgated after notice and opportunity for comment in accordance with chapter 5 of 
title 5, United States Code.". 
§10. Conforming Amendments. 
• (a) SECTION 201 - The last sentence of section 201(g)(1) (21 U.S.C. 321(g)(1)) is 
amended to read as follows: "A food or dietary supplement for which a claim, subject to 
sections 403(r)(1)(B) and 403(r)(3) or sections 403(r)(1)(B) and 403(r)(5)(D), is made in 
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accordance with the requirements of section 403(r) is not a drug solely because the label 
or the labeling contains such a claim. A food, dietary ingredient, or dietary supplement 
for which a truthful and not misleading statement is made in accordance with section 
403(r)(6) is not a drug under clause (C) solely because the label or the labeling contains 
such a statement.". 
• (b) SECTION 301 - Section 301 (21 U.S.C. 331) is amended by adding at the end the 
following: (u) The introduction or delivery for introduction into interstate commerce of a 
dietary supplement that is unsafe under section 413.". 
• (c) SECTION 403 - Section 403 (21 U.S.C. 343), as amended by section 7, is amended 
by adding after paragraph (s) the following: "A dietary supplement shall not be deemed 
misbranded solely because its label or labeling contains directions or conditions of use or 
warnings.". 
§11. Withdrawal of the Regulations and Notice. 
The advance notice of proposed rulemaking concerning dietary supplements published in the 
Federal Register of June 18, 1993 (58 FR 33690-33700) is null and void and of no force or effect 
insofar as it applies to dietary supplements. The Secretary of Health and Human Services shall 
publish a notice in the Federal Register to revoke the item declared to be null and void and of no 
force or effect under subsection (a). 
§12. Commission on Dietary Supplement Labels. 
• (a) ESTABLISHMENT. - There shall be established as an independent agency within 
the executive branch a commission to be known as the Commission on Dietary 
Supplement Labels (hereafter in this section referred to as the "Commission"). 
• (b) MEMBERSHIP. - 
o (1) COMPOSITION. - The Commission shall be composed of 7 members who 
shall be appointed by the President. 
o (2) EXPERTISE REQUIREMENT. - The members of the Commission shall 
consist of individuals with expertise and experience in dietary supplements and in 
the manufacture, regulation, distribution, and use of such supplements. At least 
three of the members of the Commission shall be qualified by scientific training 
and experience to evaluate the benefits to health of the use of dietary supplements 
and one of such three members shall have experience in pharmacognosy, medical 
botany, traditional herbal medicine, or other related sciences. Members and staff 
of the Commission shall be without bias on the issue of dietary supplements. 
• (c) FUNCTIONS OF THE COMMISSION. - The Commission shall conduct a study 
on, and provide recommendations for, the regulation of label claims and statements for 
dietary supplements, including the use of literature in connection with the sale of dietary 
supplements and procedures for the evaluation of such claims. In making such 
recommendations, the Commission shall evaluate how best to provide truthful, 
scientifically valid, and not misleading information to consumers so that such consumers 
may make informed and appropriate health care choices for themselves and their families. 
• (d) ADMINISTRATIVE POWERS OF THE COMMISSION. - 
o (1) HEARINGS. - The Commission may hold hearings, sit and act at such times 
and places, take such testimony, and receive such evidence as the Commission 
considers advisable to carry out the purposes of this section. 
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o (2) INFORMATION FROM FEDERAL AGENCIES. - The Commission may 
secure directly from any Federal department or agency such information as the 
Commission considers necessary to carry out the provisions of this section. 
o (3) AUTHORIZATION OF APPROPRIATIONS. - There are authorized to be 
appropriated such sums as may be necessary to carry out this section. 
• (e) REPORTS AND RECOMMENDATIONS. - 
o (1) FINAL REPORT REQUIRED. - Not later than 24 months after the date of 
enactment of this Act, the Commission shall prepare and submit to the President 
and to the Congress a final report on the study required by this section. 
o (2) RECOMMENDATIONS. - The report described in paragraph (1) shall contain 
such recommendations, including recommendations for legislation, as the 
Commission deems appropriate. 
o (3) ACTION ON RECOMMENDATIONS. - Within 90 days of the issuance of 
the report under paragraph (1), the Secretary of Health and Human Services shall 
publish in the Federal Register a notice of any recommendation of Commission 
for changes in regulations of the Secretary for the regulation of dietary 
supplements and shall include in such notice a notice of proposed rulemaking on 
such changes together with an opportunity to present views on such changes. 
Such rulemaking shall be completed not later than 2 years after the date of the 
issuance of such report. If such rulemaking is not completed on or before the 
expiration of such 2 years, regulations of the Secretary published in 59 FR 395-
426 on January 4, 1994, shall not be in effect. 
§13. Office of Dietary Supplements. 
• (a) IN GENERAL. - Title IV of the Public Health Service Act is amended by inserting 
after section 485B (42 U.S.C. 287c-3) the following: 
" SUBPART 4--OFFICE OF DIETARY SUPPLEMENTS SEC. 485C. DIETARY 
SUPPLEMENTS.  
o "(a) ESTABLISHMENT. - The Secretary shall establish an Office of Dietary 
Supplements within the National Institutes of Health. 
o "(b) PURPOSE. - The purposes of the Office are - 
! "(1) to explore more fully the potential role of dietary supplements as a 
significant part of the efforts of the United States to improve health care; 
and 
! "(2) to promote scientific study of the benefits of dietary supplements in 
maintaining health and preventing chronic disease and other health-related 
conditions. 
o "(c) DUTIES. - The Director of the Office of Dietary Supplements shall - 
! "(1) conduct and coordinate scientific research within the National 
Institutes of Health relating to dietary supplements and the extent to which 
the use of dietary supplements can limit or reduce the risk of diseases such 
as heart disease, cancer, birth defects, osteoporosis, cataracts, or 
prostatism; 
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! "(2) collect and compile the results of scientific research relating to dietary 
supplements, including scientific data from foreign sources or the Office 
of Alternative Medicine; 
! "(3) serve as the principal advisor to the Secretary and to the Assistant 
Secretary for Health and provide advice to the Director of the National 
Institutes of Health, the Director of the Centers for Disease Control and 
Prevention, and the Commissioner of Food and Drugs on issues relating to 
dietary supplements including - 
! "(A) dietary intake regulations; 
! "(B) the safety of dietary supplements; 
! "(C) claims characterizing the relationship between - 
! "(i) dietary supplements; and 
! "(ii)(I) prevention of disease or other health-related 
conditions; and 
! "(II) maintenance of health; and 
! "(D) scientific issues arising in connection with the labeling and 
composition of dietary supplements; 
! "(4) compile a database of scientific research on dietary supplements and 
individual nutrients; and 
! "(5) coordinate funding relating to dietary supplements for the National 
Institutes of Health. 
o "(d) DEFINITION. - As used in this section, the term "dietary supplement" has 
the meaning given the term in section 201(ff) of the Federal Food, Drug, and 
Cosmetic Act. 
o "(e) AUTHORIZATION OF APPROPRIATIONS. - There are authorized to be 
appropriated to carry out this section $5,000,000 for fiscal year 1994 and such 
sums as may be necessary for each subsequent fiscal year.". 
• (b) CONFORMING AMENDMENT. - Section 401(b)(2) of the Public Health Service 
Act (42 U.S.C. 281(b)(2)) is amended by adding at the end the following: 
o "(E) The Office of Dietary Supplements.". 
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Appendix 2 
Number of NCS Respondents by Demographic Characteristic: Comparison of Full Sample and 
Sample used in this analysis 
 Freq Percent Freq Percent 
Gender:     
Male 26,806 44.80 38,086 44.71 
Female 33,025 55.20 47,102 55.29 
Age:     
18-24 6,027 10.07 8,912 9.62 
25-34 9,118 15.24 12,370 14.52 
35-44 12,415 20.75 17,294 20.30 
45-54 12,535 20.95 17,920 21.04 
55+ 19,736 32.99 29,412 34.53 
Race:     
White 43,202 72.21 63,961 75.08 
Black 3,941 6.59 5,456 6.40 
Hispanic 9,792 16.37 12,234 14.36 
Other 2,896 4.84 3,537 4.15 
Education:     
Less than HS 7,343 12.27 10,697 12.56 
HS Grad 16,063 26.85 24,658 28.95 
Some College 16,601 27.75 23,466 27.55 
College Grad 19,552 32.68 26,054 30.58 
Income:     
< $32,500 8,076 13.50 12,664 14.87 
$32,501 - $55,000 10,636 17.78 16,294 19.13 
$55,001 - $87,500 13,599 22.73 20,013 23.59 
$87,501 - $125,000 19,426 32.47 26,197 30.75 
> $125,001 8,094 13.53 9,940 11.67 
Married Status:     
Single 11,409 19.07 15,165 17.80 
Married 38,858 64.95 56,121 65.88 
Divorce/Seperated/Widowed 9,040 15.11 13,249 15.55 
Size of Family:     
1 5,476 9.15 8,133 9.55 
2 19,820 33.13 29,939 35.14 
3 11,719 19.59 16,504 19.37 
4 11,359 18.99 15,599 18.31 
5+ 5,905 9.87 15,013 17.62 
Employment Status:     
Not Employed 20,874 34.89 30,419 35.71 
Employed 38,957 65.11 54,769 64.29 
Census Region:     
Northeast 14,984 25.04 17,750 20.84 
South 16,781 28.05 28,709 33.70 
Midwest 15,112 25.26 22,479 26.39 
West 12,954 21.65 16,250 19.08 
Total 59,831 100 85,188 100 
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